WO1990005528A2 - Anti-thrombotic steroids - Google Patents

Anti-thrombotic steroids Download PDF

Info

Publication number
WO1990005528A2
WO1990005528A2 PCT/US1989/004875 US8904875W WO9005528A2 WO 1990005528 A2 WO1990005528 A2 WO 1990005528A2 US 8904875 W US8904875 W US 8904875W WO 9005528 A2 WO9005528 A2 WO 9005528A2
Authority
WO
WIPO (PCT)
Prior art keywords
steroid
hydroxy
dione
fluoro
glucuronide
Prior art date
Application number
PCT/US1989/004875
Other languages
French (fr)
Other versions
WO1990005528A3 (en
Inventor
Moses Judah Folkman
Original Assignee
Children's Medical Center Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Medical Center Corporation filed Critical Children's Medical Center Corporation
Publication of WO1990005528A2 publication Critical patent/WO1990005528A2/en
Publication of WO1990005528A3 publication Critical patent/WO1990005528A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49Urokinase; Tissue plasminogen activator
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • This invention relates to anti-thrombotic agents, i.e., agents which operate to control or prevent the natural clot-formation process. Control or prevention of detrimental clots is im e.g., for patients at risk for myocardial infarction, stroke, or thrombosis.
  • Anti-thrombotic agents may or may not have thrombolytic activity -- i.e. the ability to dissolve a clot after it has formed. Streptokinase, urokinase, and tissue plasminogen activator are thought to be
  • One aspect of the invention features a method of controlling thrombotic activity in a mammal (particularly a human subject at risk for undesired thrombosis) by administering a therapeutic amount of an anti-thrombotic steroid (or a pharmaceutically acceptable salt thereof) to the mammal.
  • Heparin and cyclodextrin potentiate the anti- thrombotic effect of anti-thrombotic steroids.
  • another aspect of the invention features a pharmaceutical composition
  • a pharmaceutical composition comprising an effective amount of an anti-thrombotic steroid (or a
  • potentiator such as heparin or cyclodextrin sulfate.
  • the anti-thrombotic agents described herein also can be administered with other agents for controlling
  • thrombosis particularly a thrombolytic substance such as tissue plasminogen activator.
  • the steroids to be used for the purpose of the invention include anti-thrombotic compounds having a pregnane skeleton (including a norpregnane skeleton), an androstane skeleton, an estrane skeleton, a cholestane skeleton or a cholic acid skeleton, each of said
  • compounds having a C 18-21 steroid skeleton are preferably used and compounds having an pregnane (preferably 17 ⁇ -H- pregnane) skeleton, an estrane (preferably 16-alkyl- or 17-deoxy-estrane) skeleton or an androstane (preferably 16-alkyl- or 17-deoxy-androstane) skeleton are more preferably used.
  • compounds having a C 20-21 steroid skeleton such as a pregnane skeleton (C 21 ) or an 18-, 19- or 21-norpregnane skeleton (C 20 ) are used, those having a pregnane or 19-norpregnane skeleton being more preferred.
  • Steroids having a pregnane skeleton are most preferred.
  • the above skeletons may have 1 to 4 double bonds at any positions where double bonds can be formed, but double bonds are preferably unformed or formed at 1 to 3 positions selected from ⁇ 1 ' 2 , ⁇ 4 ' 5 and ⁇ 6 ' 7 .
  • the above skeletons may be substituted by a substituent or substituents such as (i) 1 to 6 hydroxyl or mercapto groups, each of said groups being
  • hydroxyl and mercapto groups may be attached to any substitutive positions of the above skeletons, but preferable are the positions 3, 16, 19 or/and 21.
  • the substituted hydroxyl and mercapto groups include a methoxy group, a tetrahydropyranyloxy group, a
  • tetrahydrofuranyloxy group an alkanoyloxy group having 1 to 20 carbon atoms (e.g. acetyloxy, propionyloxy,
  • alkenoyloxy group having 2 to 20 carbon atoms an alkenoyloxy group having 2 to 20 carbon atoms, a benzoyloxy group, a phenyl-lower alkanoyloxy group wherein the alkanoyl moiety has 2 to 5 carbon atoms, a phenyl-lower alkenoyloxy group wherein the alkenoyl moiety has 3 to 5 carbon atoms, a
  • carboxyalkylcarbonyloxy group wherein the alkyl moiety has 1 to 8 carbon atoms
  • an alkoxycarbonylalkyl- carbonyloxy group wherein the alkoxy moiety has 1 to 5 carbon atoms and the alkyl moiety has 1 to 8 carbon atoms
  • a carboxyalkenylcarbonyloxy group wherein the alkenyl moiety has 2 to 8 carbon atoms
  • alkoxycarbonylalkenylcarbonyloxy group wherein the alkoxy moiety has 1 to 5 carbon atoms and the alkenyl moiety has 2 to 8 carbon atoms, an alkanesulfonyloxy group, a phosphate group, a sulfate group, a pyranosyloxy or furanosyloxy group derived from a 5- or 6- carbon aldose, ketose, aldoketose, aldonic acid, ketoaldonic acid or aldaric acid, a pyranurono or furanurono group derived from 5- or 6-carbon uronic acid such as a
  • glucopyranurono group an alkanoylthio group having 1 to 20 carbon atoms, an alkenoylthio group having 2 to 20 carbon atoms, a benzoylthio group, a phenyl-lower
  • alkanoylthio group wherein the alkanoyl moiety has 2 to 5 carbon atoms and a phenyl-lower alkenoylthio group wherein the alkenoyl moiety has 3 to 5 carbon atoms.
  • a phenyl moiety of the above substituents having a phenyl moiety may further be substituted by 1 to 3 substituents such as a lower alkyl group having 1 to 5 carbon atoms, a lower alkoxy group having 1 to 5 carbon atoms, a halogen atom, a hydroxyl group, an amino group, a nitro group, a carboxyl group, an alkoxycarboxyl group wherein the alkoxy moiety has 1 to 5 carbon atoms.
  • a carboxyl group of the above substituents having a carboxyl moiety may be cniaternized to form a carboxylato group.
  • R 1 is a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a phenyl group or a phenyl-lower alkyl group wherein the alkyl moiety has 1 to 5 carbon atoms
  • R 2 is an alkoxy group having 1 to 5 carbon atoms, a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a phenyl group or a phenyl-lower alkyl group wherein the alkyl moiety has 1 to 5 carbon atoms, or R 1 and R 2 combined with each other to form an alkylene group having 4 to 7 carbon atoms.
  • the oxo groups may be attached to any substitutive positions of the above skeletons, but preferable are the positions 3 and/or 20.
  • halogen atoms may be attached to any substitutive positions of the above skeletons, but preferable are the positions 6, 9, 11 and/or 16.
  • the lower alkyl groups may be attached to any substitutive positions of the above skeletons, but preferable are the positions 2, 6, 7, 16 and/or 17.
  • the lower alkyl groups may be halogenated with 1 to 3 halogen atoms to form a halogenated lower alkyl group such as a trifluoromethyl group.
  • the cyano groups, the unsubstituted or substituted amino groups, the nitro groups, the cyanomethyl groups, the carboxyl groups and the carboxymethyl groups may be attached to any substitutive positions of the above skeletons, but preferable are the positions 16 and/or 17.
  • steroids those having a 17 ⁇ -H-pregnane skeleton (a pregnane skeleton having a hydrogen atom at the position 17 ⁇ ) are preferable. More preferred
  • steroids are those having a 17 ⁇ -H-pregnane skeleton which is oxygenated at the positions 3, 20 and 21, e.g. those having a 17 ⁇ -H-pregnane skeleton which has oxo groups or unsubstituted or substituted hydroxyl groups at each of the positions 3, 20 and 21, and which may have
  • the steroids may have several chiral centers in their molecule, and each isomer and a mixture of isomers can be used for the invention. Further, pharmaceutically acceptable salts of the steroids with, for example, an inorganic or organic acid, an alkali metal or an alkaline earth metal may be used.
  • Anti-thrombotic steroids are steroids found to have anti-thrombotic activity according, to the chick membrane assay described below.
  • the steroids are steroids found to have anti-thrombotic activity according, to the chick membrane assay described below.
  • Another assay for anti-thrombotic activity is as follows: A cotton pellet or a string of natural or synthetic materials is placed in the jugular vein, and thrombin and fibrinogen are locally injected into the jugular vein to produce a jugular vein thrombosis.
  • Thrombotic agents can be injected via intravenous or other routes and anti-thrombotic activity can be measured by determining the weight of the cotton pellet or string. Otherwise, thrombolysis can be measured by determining solubilized radioactivity using radioactive fibrinogen.
  • DOC desoxycorticosterone
  • deoxycorticosterone 21-hydroxypregn-4-ene-3, 20-dione; 4-pregnen-21-ol-3, 20-dione; 21- hydroxyprogesterone; 11-deoxycorticosterone; cortexone; and desoxycortone. It is a well known compound and many methods of synthesis reported in the literature. See, The Merck Index (9th Ed.) p. 379.
  • Desoxycorticosterone is believed to occur naturally as a tetraacetyl- ⁇ -D-glucoside (C 35 H 48 O 12 ). See Johnson, J. Am. Chem. Soc. 63: 3238 (1941). This and other glycosylated derivatives of desoxycorticosterone having anti-thrombotic activity are suitable for use in the present invention.
  • Other useful desoxycorticosterone derivatives include desoxycorticosterone acetate (or 21- Acetyloxypregn-
  • desoxycorticosterone are particularly preferred. They can be synthesized by the method of: Hadd, H.E. and Magnoliaenstaff, R. T., Conjugates of Steroid Hormones.
  • the anti-thrombotic activity of the steroids of the invention is generally potentiated by heparin
  • antithrombotic activity is also potentiated by cyclodextrin sulfate (particularly ⁇ -cyclodextrin tetradecasulfate).
  • tPA tissue plasminogen activator
  • the invention features mixtures having anti-thrombotic quantities of an anti-thrombotic steroid and heparin, cyclodextrin, or tPA.
  • the mixtures are compounded in a suitable physiologically acceptable vehicle and administered, to provide 50-150 ⁇ g/ ⁇ l of the desoxycorticosterone component at the desired site.
  • Systemic routes of administration include i.v. and oral.
  • the anti-thrombotic desoxycorticosterone glucuronides are water soluble and are absorbed through the
  • Fluorinated analogues of desoxycorticosterone can be prepared by known techniques. See generally,
  • anti-thrombotic steroids anti-thrombotic potentiators such as heparin and cyclodextrin
  • thrombolytic substances such as TPA, which are to be used in accordance with the present invention, have low toxicity.
  • the dose of the anti-thrombotic steroids depends on the mode of use, purpose of use and other factors.
  • the effective amount is in a proportion of about 0.5 to 100 mg/kg, preferably about 1 to 30 mg/kg, when used alone, and in a proportion of about 0.5 to 50 mg/kg, preferably about 1 to 20 mg/kg, when used in combination with anti-thrombotic potentiators or thrombolytic
  • Anti-thrombotic potentiators such as heparin and cyclodextrin are used in a ratio of about 1/10 to 2 times weight equivalents, preferably about 1/5 to 1/2 time weight equivalent to each weight equivalent of the anti- thrombotic steroids.
  • Thrombolytic substances such as TPA are used in a ratio of about 1/10 to two times weight equivalent, preferably about 1/5 to 1 time weight
  • the anti-thrombotic potentiators or thrombolytic substances are administered in combination with the anti-thrombotic steroids orally or non-orally.
  • the dose of the anti- thrombotic agent according to the present invention may vary also depending on the kind of anti-thrombotic steroids, anti-thrombotic potentiators or thrombolytic substances employed. Generally, the effective amount of the daily does for a warm-blooded mammals (e.g. mouse, cat, dog, cattle, sheep, goat, rabbit, human) as
  • expressed in terms of the anti-thrombotic steroids is preferably about 0.5 to 20 mg/kg in a form of injections, about 0.5 to 50 mg/kg in a form of drip infusion
  • anti-thrombotic agent which comprises anti-thrombotic steroids or anti-thrombotic potentiators and/or thrombolytic
  • substances can be formulated for administration by mixing the substance or substances according to an appropriate known pharmaceutical process, using, as desired, one or more pharmaceutically acceptable carriers (including diluents, excipients and the like). It is also possible to make up the respective substances into separate preparations or combine these active substances at the time of use into a single preparation containing them for administration by using a diluent, for instance. It is further possible to administer the above separate pharmaceutically acceptable carriers (including diluents, excipients and the like). It is also possible to make up the respective substances into separate preparations or combine these active substances at the time of use into a single preparation containing them for administration by using a diluent, for instance. It is further possible to administer the above separate
  • physiological saline and human serum albunim-suplemented distilled water or phasiological salins physiological saline and human serum albunim-suplemented distilled water or phasiological salins.
  • distilled water physiological saline
  • dextran sulfate solution distilled water, physiological saline, dextran sulfate solution.
  • ointment bases such as glycerin, sodium lauryl sulfate, polyethylene glycol ointment, white wax etc. are usable.
  • the preparations of the present invention are made up in conventional manners emplying the said carrier. Those steroids with anti-thrombotic activity may be used for prevention and therapy for thromboembolic diseases, cardiac infarction, traumatism, thrombosis associated with extracorporal circulation.
  • DOC desoxycorticosterone
  • P.A.I. plasminogen activator inhibitor
  • Ethanolic solution of a steroid 100 ⁇ g/ml was added to culture of human umbelic vein endothelial cells (H ⁇ VE), and medium was removed on the next day to determine PAI- 1.
  • PAI-1 was measured by the enzyme-linked immunosorbent assay (ELISA) of Declerck et al. (P. Declerck et al.: Blood: 71, 220 (1988)) as follows. Two murine
  • monoclonal antibodies raised against human PAI-1 were used as a two-site ELISA assay. Wells of microtiter plates were coated with the first antibody, followed by a sample addition, washing, and the second antibody. The bound immunoglobulins were detected with horseradish peroxidase-conjugated rabbit antimouse IgG. The anti- thrombotic steroids decreased PAI-1 concentrations to less than 50% of the control (no. steroid) level.
  • HPC-L hydroxypropylcellulose 10 g
  • the above four materials were mixed under aseptic conditions in the above proportions and then dissolved or suspended in distilled water (2000 ml) for injection or physiological saline and, following addition of human serum albumin (HSA) in a concentration of 0.5%.
  • HSA human serum albumin
  • the above four materials were mixed under aseptic conditions in the above proportions and dissolved or suspended in distilled water (2000 ml) for injection or physiological saline and, following addition of human serum akbumin (HSA) in a concentration of 0.5%.
  • HSA human serum akbumin
  • the above three materials were mixed under aseptic conditions in the above proportions and dissolved or suspended in distilled water (2000 ml) for injection or physiological saline and, following addition of human serum albumin (HSA) in a concentration of 0.5 ⁇ .
  • HSA human serum albumin
  • Tetrahydrodesoxycorticosterone 21-glucuronide (150 ⁇ g/10 ⁇ l) was administered to 9th day chick
  • chorioallantoic membranes by known techniques such as the one described in Follaner et al. Nature 297:307 et seq. (1982), and the membranes were evaluated for a hemorrhage of at least 2mm, which was characteristic of a strong positive result. The membranes test was strongly positive for anti-thrombotic activity.
  • Example 1 The procedure of Example 1 was followed using tetrahydrodesoxycorticorterone 3-glucuronide (150
  • Example 1 The procedure of Example 1 was followed using tetrahydrodesoxycorticorterone 3,21 diglucuronide (150 ⁇ g/10 ⁇ l), yielding strong positive results.
  • Example 1 The procedure of Example 1 was followed using desoxycorticosterone 21-glucuronide (150 ⁇ g/ ⁇ l), yielding positive results in a majority of the membranes tested.
  • Example 6 The procedure of Example 1 was followed using tetrahydro-desoxycorticosterone (150 ⁇ g/ ⁇ l), yielding strong positive results in a substantial percentage of the membranes tested.
  • Example 6 tetrahydro-desoxycorticosterone (150 ⁇ g/ ⁇ l), yielding strong positive results in a substantial percentage of the membranes tested.
  • Example 7 The procedure of Example 1 was followed using tetrahydro-desoxycorticosterone 3-acetate (15 ⁇ g/ ⁇ l), yielding strong positive results in a substantial percentage of the membranes tested.
  • Example 1 The procedure of Example 1 was followed using didehydro-desoxycorticosterone 21-acetate, yielding strong positive results in some of the membranes tested.
  • Example 1 The procedure of Example 1 was followed with desoxycorticosterone at 150 ⁇ g/10 ⁇ l and at 100 ⁇ g/10 ⁇ l, yielding strong positive results in an increasing percentage of membranes at the higher dosage.
  • Example 1 The procedure of Example 1 was followed using desoxycorticosterone (150 ⁇ g/10 ⁇ l) with heparin (50 ⁇ g/1 ⁇ ), yielding strong positive results in a higher percentage of the membranes tested than was the case in Examples 8 and 9.
  • Example 1 The procedure of Example 1 was used with Desoxycorticosterone (100 ⁇ g/10 ⁇ l) and tPA (ActivaseTM Genentech, 200 ⁇ g/10 ⁇ l), yielding a substantial
  • Example 9 The procedure of Example 1 was followed with desoxycorticosterone (100 ⁇ g/10 ⁇ l) and ⁇ -cyclodextrin tetradecasulfate (25 ⁇ g/10 ⁇ l). The incidence of strong positive results was significantly higher than with desoxycorticosterone alone (Example 9).
  • CAM shell-less chorioallantoic membrane
  • antithrombotic activity is indicated by the symbol "++", when as little as 50 ⁇ g of the steroid in 10 ⁇ l mixture shows a strong positive result (a hemorrhage of at least 2mm) .
  • Strong antithrombotic activity is indicated by the symbol "+++” when as little as 20 ⁇ g of the steroid in that solution shows a strong positive result.
  • a strong positive result at 150 ⁇ g/10 ⁇ l is shown by the symbol "+".
  • the steroids are generally described in the following literature and/or are synthesized by the same methods shown in the literature. For example, see:

Abstract

Anti-thrombotic compositions include anti-thrombotic steroids together with potentiators thereof (e.g. heparin or cyclodextrin) or with a thrombolytic substance such as tissue plasminogen activator. Therapy, in which thrombosis in a mammal at risk is prevented or treated, comprises administering an effective amount of a steroid possessing anti-thrombotic activity or a pharmaceutically acceptable salt thereof.

Description

ANTI-THROMBOTIC STEROIDS
Background of the Invention
This invention relates to anti-thrombotic agents, i.e., agents which operate to control or prevent the natural clot-formation process. Control or prevention of detrimental clots is im e.g., for patients at risk for myocardial infarction, stroke, or thrombosis.
Anti-thrombotic agents may or may not have thrombolytic activity -- i.e. the ability to dissolve a clot after it has formed. Streptokinase, urokinase, and tissue plasminogen activator are thought to be
thrombolytic agents.
Summary of the Invention
One aspect of the invention features a method of controlling thrombotic activity in a mammal (particularly a human subject at risk for undesired thrombosis) by administering a therapeutic amount of an anti-thrombotic steroid (or a pharmaceutically acceptable salt thereof) to the mammal.
Heparin and cyclodextrin potentiate the anti- thrombotic effect of anti-thrombotic steroids.
Accordingly, another aspect of the invention features a pharmaceutical composition comprising an effective amount of an anti-thrombotic steroid (or a
pharmaceutically acceptable salt thereof) and a
potentiator such as heparin or cyclodextrin sulfate. The anti-thrombotic agents described herein also can be administered with other agents for controlling
thrombosis, particularly a thrombolytic substance such as tissue plasminogen activator. Description of the Preferred Embodiments
The steroids to be used for the purpose of the invention include anti-thrombotic compounds having a pregnane skeleton (including a norpregnane skeleton), an androstane skeleton, an estrane skeleton, a cholestane skeleton or a cholic acid skeleton, each of said
skeletons being unsubstituted or substituted, and having or not having a double bond therein. Among them,
compounds having a C18-21 steroid skeleton are preferably used and compounds having an pregnane (preferably 17α-H- pregnane) skeleton, an estrane (preferably 16-alkyl- or 17-deoxy-estrane) skeleton or an androstane (preferably 16-alkyl- or 17-deoxy-androstane) skeleton are more preferably used. Also, compounds having a C20-21 steroid skeleton such as a pregnane skeleton (C21) or an 18-, 19- or 21-norpregnane skeleton (C20) are used, those having a pregnane or 19-norpregnane skeleton being more preferred. Steroids having a pregnane skeleton are most preferred.
The above skeletons may have 1 to 4 double bonds at any positions where double bonds can be formed, but double bonds are preferably unformed or formed at 1 to 3 positions selected from Δ1'2, Δ4'5 and Δ6'7.
The above skeletons may be substituted by a substituent or substituents such as (i) 1 to 6 hydroxyl or mercapto groups, each of said groups being
unsubstituted or substituted, (ii) 1 to 4 oxo groups, (iii) 1 to 4 halogen atoms, (iv) 1 to 3 lower alkyl groups having 1 to 5 carbon atoms which may be
halogenated, (v) 1 or 2 cyano groups, (vi) 1 or 2 amino groups which may be substituted by 1 or 2 lower alkyl groups having 1 to 5 carbon atoms, a lower alkanoyl group having 2 to 5 carbon atoms or a benzoyl group, (vii) 1 or 2 nitro groups, (viii) 1 or 2 cyanomethyl groups, (ix) 1 or 2 carboxyl groups or (x) 1 or 2 qarboxymethyl groups. The hydroxyl and mercapto groups may be attached to any substitutive positions of the above skeletons, but preferable are the positions 3, 16, 19 or/and 21. The substituted hydroxyl and mercapto groups include a methoxy group, a tetrahydropyranyloxy group, a
tetrahydrofuranyloxy group, an alkanoyloxy group having 1 to 20 carbon atoms (e.g. acetyloxy, propionyloxy,
lauroyloxy), an alkenoyloxy group having 2 to 20 carbon atoms, a benzoyloxy group, a phenyl-lower alkanoyloxy group wherein the alkanoyl moiety has 2 to 5 carbon atoms, a phenyl-lower alkenoyloxy group wherein the alkenoyl moiety has 3 to 5 carbon atoms, a
carboxyalkylcarbonyloxy group wherein the alkyl moiety has 1 to 8 carbon atoms, an alkoxycarbonylalkyl- carbonyloxy group wherein the alkoxy moiety has 1 to 5 carbon atoms and the alkyl moiety has 1 to 8 carbon atoms, a carboxyalkenylcarbonyloxy group wherein the alkenyl moiety has 2 to 8 carbon atoms, an
alkoxycarbonylalkenylcarbonyloxy group wherein the alkoxy moiety has 1 to 5 carbon atoms and the alkenyl moiety has 2 to 8 carbon atoms, an alkanesulfonyloxy group, a phosphate group, a sulfate group, a pyranosyloxy or furanosyloxy group derived from a 5- or 6- carbon aldose, ketose, aldoketose, aldonic acid, ketoaldonic acid or aldaric acid, a pyranurono or furanurono group derived from 5- or 6-carbon uronic acid such as a
glucopyranurono group, an alkanoylthio group having 1 to 20 carbon atoms, an alkenoylthio group having 2 to 20 carbon atoms, a benzoylthio group, a phenyl-lower
alkanoylthio group wherein the alkanoyl moiety has 2 to 5 carbon atoms and a phenyl-lower alkenoylthio group wherein the alkenoyl moiety has 3 to 5 carbon atoms. A phenyl moiety of the above substituents having a phenyl moiety may further be substituted by 1 to 3 substituents such as a lower alkyl group having 1 to 5 carbon atoms, a lower alkoxy group having 1 to 5 carbon atoms, a halogen atom, a hydroxyl group, an amino group, a nitro group, a carboxyl group, an alkoxycarboxyl group wherein the alkoxy moiety has 1 to 5 carbon atoms. A carboxyl group of the above substituents having a carboxyl moiety may be cniaternized to form a carboxylato group.
Two of the hydroxyl groups may also combined to form a ketal of the formula:
Figure imgf000006_0001
wherein R1 is a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a phenyl group or a phenyl-lower alkyl group wherein the alkyl moiety has 1 to 5 carbon atoms, and R2 is an alkoxy group having 1 to 5 carbon atoms, a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a phenyl group or a phenyl-lower alkyl group wherein the alkyl moiety has 1 to 5 carbon atoms, or R1 and R2 combined with each other to form an alkylene group having 4 to 7 carbon atoms.
The oxo groups may be attached to any substitutive positions of the above skeletons, but preferable are the positions 3 and/or 20.
The halogen atoms (preferably fluorine atoms) may be attached to any substitutive positions of the above skeletons, but preferable are the positions 6, 9, 11 and/or 16.
The lower alkyl groups may be attached to any substitutive positions of the above skeletons, but preferable are the positions 2, 6, 7, 16 and/or 17. The lower alkyl groups may be halogenated with 1 to 3 halogen atoms to form a halogenated lower alkyl group such as a trifluoromethyl group. The cyano groups, the unsubstituted or substituted amino groups, the nitro groups, the cyanomethyl groups, the carboxyl groups and the carboxymethyl groups may be attached to any substitutive positions of the above skeletons, but preferable are the positions 16 and/or 17.
Among the steroids, those having a 17α-H-pregnane skeleton (a pregnane skeleton having a hydrogen atom at the position 17α) are preferable. More preferred
steroids are those having a 17α-H-pregnane skeleton which is oxygenated at the positions 3, 20 and 21, e.g. those having a 17α-H-pregnane skeleton which has oxo groups or unsubstituted or substituted hydroxyl groups at each of the positions 3, 20 and 21, and which may have
substituents as mentioned above at any other substitutive positions. Those are preferably unoxygenated at the position 11
The steroids may have several chiral centers in their molecule, and each isomer and a mixture of isomers can be used for the invention. Further, pharmaceutically acceptable salts of the steroids with, for example, an inorganic or organic acid, an alkali metal or an alkaline earth metal may be used.
The above steroids can be prepared according to the methods described in J. Fried and J. A. Edwards, "Organic Reactions in Steroid Chemistry", Vols. l and 2, van Nostrand Reinhold Company, New York, 1972; L. Fieser and M. Fieser, "Steroids", Reinhold Publishing
Corporation, 1959; and N. Applezweig, "Steroid Drugs", McGraw-Hill Book Company, Inc., 1962, or similar methods thereto.
Anti-thrombotic steroids are steroids found to have anti-thrombotic activity according, to the chick membrane assay described below. The steroids
specifically enumerated in Appendix I are examples of steroids that can be evaluated for anti-thrombotic
activity according to that assay.
Another assay for anti-thrombotic activity is as follows: A cotton pellet or a string of natural or synthetic materials is placed in the jugular vein, and thrombin and fibrinogen are locally injected into the jugular vein to produce a jugular vein thrombosis.
Thrombotic agents can be injected via intravenous or other routes and anti-thrombotic activity can be measured by determining the weight of the cotton pellet or string. Otherwise, thrombolysis can be measured by determining solubilized radioactivity using radioactive fibrinogen.
One particular anti-thrombotic steroid is desoxycorticosterone ("DOC"), which has the following structure:
Figure imgf000008_0001
Several other names are sometimes used to designate this compound: deoxycorticosterone; 21-hydroxypregn-4-ene-3, 20-dione; 4-pregnen-21-ol-3, 20-dione; 21- hydroxyprogesterone; 11-deoxycorticosterone; cortexone; and desoxycortone. It is a well known compound and many methods of synthesis reported in the literature. See, The Merck Index (9th Ed.) p. 379.
Desoxycorticosterone is believed to occur naturally as a tetraacetyl-β-D-glucoside (C35H48O12). See Johnson, J. Am. Chem. Soc. 63: 3238 (1941). This and other glycosylated derivatives of desoxycorticosterone having anti-thrombotic activity are suitable for use in the present invention. Other useful desoxycorticosterone derivatives include desoxycorticosterone acetate (or 21- Acetyloxypregn-
4-ene-3,20-dione), which is available under several tradenames. See The Merck Index. cited above.
Anti-thrombotic glucuronides of
desoxycorticosterone are particularly preferred. They can be synthesized by the method of: Hadd, H.E. and Blickenstaff, R. T., Conjugates of Steroid Hormones.
Academic Press, New York, New York (1969); or Hadd et al., J. Steroid Biochem. 18:81-87 (1983).
The anti-thrombotic activity of the steroids of the invention is generally potentiated by heparin
(commerically available dextran sulfate) and heparin fragments. Antithrombotic activity is also potentiated by cyclodextrin sulfate (particularly β-cyclodextrin tetradecasulfate). The antithrombotic compositions discussed above potentiate the thrombolytic activity of tissue plasminogen activator (tPA).
Accordingly, the invention features mixtures having anti-thrombotic quantities of an anti-thrombotic steroid and heparin, cyclodextrin, or tPA. The mixtures are compounded in a suitable physiologically acceptable vehicle and administered, to provide 50-150 μg/μl of the desoxycorticosterone component at the desired site.
Systemic routes of administration include i.v. and oral. The anti-thrombotic desoxycorticosterone glucuronides are water soluble and are absorbed through the
gastrointestinal tract, making them particularly suitable for oral administrations. Moreover, some of these compounds are known to occur naturally in the human body.
Fluorinated analogues of desoxycorticosterone can be prepared by known techniques. See generally,
Bergstrom et al. J. Qrg. Chem. 28:2633-2640 (1963). In the present invention, among the above anti- thrombotic steroids, DOC, tetrahydrocorticosterone and their acetate or glucronide derivatives, 21-acetoxy- 11β, 17α-dihydroxypregne-4,6-dieno-3 , 20- dione, 17β- acetoxy-3α-hydroxy-5β-estrane and 11β, 17β-dihydroxy-6- methylene-17α-(2- hydroxycarboxylethyl)-androst-4-en-3- one-17-lactone are preferable.
The anti-thrombotic steroids, anti-thrombotic potentiators such as heparin and cyclodextrin, and thrombolytic substances such as TPA, which are to be used in accordance with the present invention, have low toxicity.
The dose of the anti-thrombotic steroids depends on the mode of use, purpose of use and other factors.
The effective amount is in a proportion of about 0.5 to 100 mg/kg, preferably about 1 to 30 mg/kg, when used alone, and in a proportion of about 0.5 to 50 mg/kg, preferably about 1 to 20 mg/kg, when used in combination with anti-thrombotic potentiators or thrombolytic
substances.
Anti-thrombotic potentiators such as heparin and cyclodextrin are used in a ratio of about 1/10 to 2 times weight equivalents, preferably about 1/5 to 1/2 time weight equivalent to each weight equivalent of the anti- thrombotic steroids. Thrombolytic substances such as TPA are used in a ratio of about 1/10 to two times weight equivalent, preferably about 1/5 to 1 time weight
equivalent of the anti-thrombotic steroids. The anti- thrombotic potentiators or thrombolytic substances are administered in combination with the anti-thrombotic steroids orally or non-orally. The dose of the anti- thrombotic agent according to the present invention may vary also depending on the kind of anti-thrombotic steroids, anti-thrombotic potentiators or thrombolytic substances employed. Generally, the effective amount of the daily does for a warm-blooded mammals (e.g. mouse, cat, dog, cattle, sheep, goat, rabbit, human) as
expressed in terms of the anti-thrombotic steroids is preferably about 0.5 to 20 mg/kg in a form of injections, about 0.5 to 50 mg/kg in a form of drip infusion
preparations, about 2 to 10 mg/kg in a form of
preparation for percutaneous absorption.
The anti-thrombotic agent according to the present invention which comprises anti-thrombotic steroids or anti-thrombotic potentiators and/or thrombolytic
substances can be formulated for administration by mixing the substance or substances according to an appropriate known pharmaceutical process, using, as desired, one or more pharmaceutically acceptable carriers (including diluents, excipients and the like). It is also possible to make up the respective substances into separate preparations or combine these active substances at the time of use into a single preparation containing them for administration by using a diluent, for instance. It is further possible to administer the above separate
preparations to the same subject either simultaneously or at a certain time interval.
When preparing an agent for injection, as the carrier, there are mentioned distilled water,
physiological saline and human serum albunim-suplemented distilled water or phasiological salins.
As the carrier for an agent for drip infusion preparations, there are mentioned distilled water, physiological saline, dextran sulfate solution.
As the carrier for an agent for precutaneous absorption, several kinds of ointment bases such as glycerin, sodium lauryl sulfate, polyethylene glycol ointment, white wax etc. are usable.
The preparations of the present invention are made up in conventional manners emplying the said carrier. Those steroids with anti-thrombotic activity may be used for prevention and therapy for thromboembolic diseases, cardiac infarction, traumatism, thrombosis associated with extracorporal circulation.
These may be used as powders or as ingredients in therapeutic mixtures for mammals (human, rabbit, dog, cat, rat, mouse etc.) via oral or other routes. When used for prevention or therapy of cardiac infarction, desoxycorticosterone (DOC) can be used at the dose of 0.5-100 mg/kg, favorably 1-30 mg/kg by intravenous administration; 0.15-15 mg/kg. Without wishing to bind myself to any particular theory, it appears that the mechanism of action at issue involves suppression of plasminogen activator inhibitor (P.A.I.), reported by Loskutoff et al. J. Biol. Chem. 256:4142 (1981). This mechanism was supported by data indicating that the DOC inhibits P.A.I., which was determined as follows.
Ethanolic solution of a steroid (100 μg/ml) was added to culture of human umbelic vein endothelial cells (HϋVE), and medium was removed on the next day to determine PAI- 1. PAI-1 was measured by the enzyme-linked immunosorbent assay (ELISA) of Declerck et al. (P. Declerck et al.: Blood: 71, 220 (1988)) as follows. Two murine
monoclonal antibodies raised against human PAI-1 were used as a two-site ELISA assay. Wells of microtiter plates were coated with the first antibody, followed by a sample addition, washing, and the second antibody. The bound immunoglobulins were detected with horseradish peroxidase-conjugated rabbit antimouse IgG. The anti- thrombotic steroids decreased PAI-1 concentrations to less than 50% of the control (no. steroid) level.
The following examples are provided to illustrate the. invention, not to limit it. Examples of Therapeutic Preparations
Preparation Example A
(Injectable preparation)
Steroid:DOC 20 g β-cyclodextrintetradecasulfate 10 g
Lactose 20 g
HPC-L (hydroxypropylcellulose) 10 g
Total 60 g
The above four materials were mixed under aseptic conditions in the above proportions and then dissolved or suspended in distilled water (2000 ml) for injection or physiological saline and, following addition of human serum albumin (HSA) in a concentration of 0.5%. The solution thus obtained was distributed in 2-ml portions into vials under aseptic conditions to give 1000 vials of an anti-thrombotic preparation for injection.
Preparation Example B
(Injectable preparation)
Steroid:DOC 10 g Heparin 2.5 g
Lactose 12.5 g
HPC-L 5 g
Total 30 g
The above four materials were mixed under aseptic conditions in the above proportions and dissolved or suspended in distilled water (2000 ml) for injection or physiological saline and, following addition of human serum akbumin (HSA) in a concentration of 0.5%. The solution thus obtained was distributed in 2-ml portions into vials under aseptic conditions to give 1000 vials of an anti-thrombotic preparation for injection.
Preparation Example C
(Injectable preparation)
Steroid:DOC 20 g
TPA 100 g
Lactose 20 g
HPC-L fhvdroxvprooylcellulose} 20 g
Total 160 g The above four materials were mixed under aseptic conditions in the above proportions and then dissolved or suspended in distilled water (3000 ml) for injection or physiological saline and, following addition of human serum albumin (HSA) in a concentration of 0.5%. The solution thus obtained was distributed in 3-ml portions into vials under aseptic conditions to give 1000 vials of an anti-thrombotic preparation for injection.
Preparation Example D
(Injectable preparation) Steroid:DOC 20 g
Lactose 30 g
HPC-L 10 g
Total 60 g
The above three materials were mixed under aseptic conditions in the above proportions and dissolved or suspended in distilled water (2000 ml) for injection or physiological saline and, following addition of human serum albumin (HSA) in a concentration of 0.5Φ. The solution thus obtained was distributed under aseptic conditions in 1-ml portions into vials to give 1000 vials of an anti-thrombotic preparation for injection.
Preparation Example E
(Oral preparation) (1) Steroid:DOC 15 g
(2) Lactose 135 g
(3) Corn starch 45 g
(4) Magnesium stearate 5 g
Total 200 g The above material (1), (2) and 25 g of (3) were blended, and granulated together with a paste prepared from 10 g of the material (3) and 25 ml of water. 10 g of the material (3) and the material (4) were added to the resulting granules, and the mixture was compressed by a tabletting machine to prepare 1000 tablets of diameter 6 mm each containing 15 mg of the material (1).
ANTI-THROMBOTIC EXAMPLES
Example 1
Tetrahydrodesoxycorticosterone
21-Glucuronide
Tetrahydrodesoxycorticosterone 21-glucuronide (150 μg/10μl) was administered to 9th day chick
chorioallantoic membranes, by known techniques such as the one described in Follaner et al. Nature 297:307 et seq. (1982), and the membranes were evaluated for a hemorrhage of at least 2mm, which was characteristic of a strong positive result. The membranes test was strongly positive for anti-thrombotic activity. Example 2
Tetrahydrodesoxycorticosterone
3-Glucuronide
The procedure of Example 1 was followed using tetrahydrodesoxycorticorterone 3-glucuronide (150
μg/10μl), yielding strong positive results.
Example 3
Tetrahydrodesoxycorticosterone
3. 21-Diglucuronide
The procedure of Example 1 was followed using tetrahydrodesoxycorticorterone 3,21 diglucuronide (150 μg/10μl), yielding strong positive results.
Example 4
Desoxycorticosterone
21-Glucuronide
The procedure of Example 1 was followed using desoxycorticosterone 21-glucuronide (150 μg/μl), yielding positive results in a majority of the membranes tested.
Example 5
Tetrahydro-Desoxycorticosterone
The procedure of Example 1 was followed using tetrahydro-desoxycorticosterone (150 μg/μl), yielding strong positive results in a substantial percentage of the membranes tested. Example 6
Tetrahydro-Desoxycorticosterone
3-Acetate
The procedure of Example 1 was followed using tetrahydro-desoxycorticosterone 3-acetate (15 μg/μl), yielding strong positive results in a substantial percentage of the membranes tested. Example 7
Dihydro-Desoxycorticosterone
21-Ace tate
The procedure of Example 1 was followed using didehydro-desoxycorticosterone 21-acetate, yielding strong positive results in some of the membranes tested.
Examples 8 and 9
Desoxycorticosterone
The procedure of Example 1 was followed with desoxycorticosterone at 150 μg/10μl and at 100 μg/10μl, yielding strong positive results in an increasing percentage of membranes at the higher dosage.
Example 10
Desoxycorticosterone
Plus Heparin
The procedure of Example 1 was followed using desoxycorticosterone (150 μg/10μl) with heparin (50 μg/1μ), yielding strong positive results in a higher percentage of the membranes tested than was the case in Examples 8 and 9.
Examples 11 and 12
Desoxycorticosterone
and tPA
The procedure of Example 1 was used with Desoxycorticosterone (100 μg/10μl) and tPA (Activase™ Genentech, 200 μg/10μl), yielding a substantial
percentage of strong positive results. Reducing the dosage of tPA to 100 μg/10μl reduced, but did not eliminate, the incidence of strong positive results. Example 13
Desoxycorticosterone
and β-Cyclodextrin
The procedure of Example 1 was followed with desoxycorticosterone (100 μg/10μl) and β-cyclodextrin tetradecasulfate (25 μg/10μl). The incidence of strong positive results was significantly higher than with desoxycorticosterone alone (Example 9).
Examples 14-54
The anti-thrombotic activity of each compound listed below was tested in the shell-less chorioallantoic membrane (CAM) assay, generally as described in Taylor and Folkman et al. Nature 297:307 et seq. (1982). The 3- day-chick embryos were removed from their shells and cultured in plastic cups on hammocks of plastic wrap. An ethanolic solution of steroid was mixed with 1%
methylcellulose (1:1) and 10 μl of this mixture at 20- 150 μl of steroid per 10 μl of mixture was dried and placed on the CAM of the embryos.
Bleeding was observed the next day under a stereoscope. In the following table, antithrombotic activity is indicated by the symbol "++", when as little as 50 μg of the steroid in 10 μl mixture shows a strong positive result (a hemorrhage of at least 2mm) . Strong antithrombotic activity is indicated by the symbol "+++" when as little as 20 μg of the steroid in that solution shows a strong positive result. A strong positive result at 150 μg/10μl is shown by the symbol "+".
The steroids are generally described in the following literature and/or are synthesized by the same methods shown in the literature. For example, see:
G. Golo et al., Chem. Pharm. Bull., 21, 1893 (1973); G. Goto et al., Tetrahedron, 30, 2107 (1974); G. Goto et al., Bull. Chem. Soc. Jpn., 50, 186 (1977); G. Goto et al., Chem. Pharm. Bull., 25, 1295 (1977); G. Goto et al., Chem. Parm. Bull., 26, 1718 (1973); X.
Yoshioka et al., Chem. Comm., 1971, 336; K. Yoshioka et al., Chem. Pharm. Bull., 23, 3203 (1975); Y. Yosuoka et al., Yakugaku Zasshi, 103, 1045 (1983).
PREGNANES
Example No. Compound Result
14. 11β, 17α, 21-trihydroxypregne-1,
4-diene-3 , 20-dionel7α, 21-methyl- orthoacetate ++
15, 11β,17α,21-trihydroxypregne-1,
4-diene-3,20-dionel7α,21- acetonide ++
16, 20,21-diacetoxy-11β-hydroxy- 17α,20-epoxy-16α-(1,2- dihydroxy-ethyl)pregne-1,4- dien-3-one ++
17. 21-acetoxy-11β,17α- dihydroxypregne-4,6-dieno- 3,20-dione +++
18. 9α-fluoro-11α,17α,21,22- tetrahydroxy-16α-methylpregne- 1,4-dien-3-one +++
19. 17α,21-diacetoxy-11α- hydroxypregn-4-en-3,20-dione ++ 20. 9α-fluoro-11α,17α,20,21- tetrahydroxy-16α-methylpregne- 1, 4-dien-3-one +++
21. 9α-fluoro-1α-thioaeetyl- 17α,21-dipropionyloxy-11α- hydroxy-16α-methylpregn- 4-en-3-one ++
22. 9α-fluoro-17α,21- dipropionyloxy-11α-acetoxy- 16α-methylpregno-1,4-diene-3, 20-dione ++ 23. 21-acetoxy-llα-hydroxy-16E- nitromethylpregne-1,4-diene- 3,20-dione ++
24. 20,21-diacetoxyy-11α-hydroxy-
16α-vinylpregne-1,4,17(20)- trien-3-one ++
25. 20,21-dihydroxypregne-4-en-3-one +++
ESTRANES
26. 17β-acetoxy-3α-hydroxy-5β- estrane +++ 27. 17β-propionyloxy-18B-ethylestr-
4-en-3-one
28. 17β-hydroxy-16α-propylestr-
4-en-3-one ++
29. 17β-hydroxy-18-vinylestr-4- en-3-one +++ 30. 17β-hydroxy-16α-vinylestr-
4-en-3-one ++
31. 16β, 17β-dihydroxy-3-methoxyestra-
1,3, 5 (10)-triene ++ 32. 16β,17β-dihydroxy-3-methoxy-
16α-ethylestra-1,3,5(10)-triene +++
33. 3-hydroxy-16-ethylestra-1,3,
5 (10),18-tetraene +++
34. 17β-hydroxy-16α-ethylestr- 4-en-3-one +++
35. 3 ,17β-dihydroxy-18β-ethylestra-
1,3,5(10)-triene +++
36. 17β-monosuccinyloxy-3-methoxy-
6,6-dimethylestra-1,35(10)-triene +++ 37. 17β-monosuuccinyloxy-3- methoxyestra-1,3,5(10)-triene ++
38. 16β,17β-dihydroxy-16α- methylestr-4-en-3-one +++
39. 5-chloro-17β-hydroxyestra- 4,5-dien-3-one +++
ANDROSTANES
40. 11β,17β-dihyidroxy-6-methylene- 17α-(2-hydroxycarbonylethyl)- androst-4-en-3-one17-lactone +++
41. 11β-tetrahydrpyranyloxy-3- methoxyandrosta-3,5(6)-dien-17-one ++
42. 3β-acetoxy-7e-hydroxyandrost-4- en-17-one ++
43. 3-methoxyandrosta-3,5(6)-diene +++
44. 3-ethoxyandrosta-3,5(6)-dien-
17-one ++
45. 3α,4α-epoxy-5β- hydroxycarbonylmethylandrostan-
17β-o1 ++
46. 16α,17α-dihydroxy-16β-(1,1- dimethyl-3-hydroxycarbonylethy1)- androsta-4,6-dien-3-one16-lactone ++ 47. androsta-1,4,6-trien-3-one ++
48. 2-formyl-3-methoxyandrosta- 2,4-diene ++
49. 6-ethylidenandrost-4-en-3-one ++
50. 17β-acetoxy-3-methoxyandrosta- 3,5(6)-diens ++
51. 17β-acetoxy-3-methoxy-3- formylandrpsta-3,5(6)-diene ++
52. 6-chloro-l7β-hydroxy-16β- methylandrosta-4,6-dien-3-one ++
53. 17β-hydroxycarbonyl-17α- hydroxyandrost-4-en-3-one +++
54. 17β-hydroxycarbonyl-17α- hydroxyandrosta-1,4-dien-3-one +++
Other embodiments are within the following claims.
Appendix
21-hydroxypregn-4-ene-3,20-dione (11-desoxycorticosterone) 2.-fluoro-21-hydroxypregn-4-ene-3,20-dione
4-chloro-21-hydroxypregn-4-ene-3,20-dione
4-fluoro-21-hydroxypregn-4-ene-3,20-dione
4-iodo-21-hydroxypregn-4-ene-3,20-dione
6α-chloro-21-hydroxypregn-4-ene-3,20-dione
6α-fluoro-21-hydroxypregn-4-ene-3,20-dione
6β-fluoro-21-hydroxypregn-4-ene-3,20-dione
9α-chloro-21-hydroxypregn-4-ene-3,20-dione
9α-broιιo-21-hydroxypregn-4-ene-3,20-dione
9α-fluoro-21-hydroxypregn-4-ene-3,20-dione
11α-chioro-21-hydroxypregn-4-ene-3.20-dione
11α-bromo-21-hydroxypregn-4-ene-3,20-dione
11α-fluoro-21-hydroxypregn-4-ene-3,20-dione
12α-fluoro-21-hydroxypregn-4-ene-3,20-dione
16α-chloro-21-hydroxypregn-4-ene-3,20-dione
16α-fluoro-21-hydroxypregn-4-ene-3,20-dione
17α-fluoro-21-hydroxypregn-4-ene-3,20-dione
19-fluoro-21-hydroxypregn-4-ene-3,20-dione 6α. 9α-difluoro-21-hydroxypregn-4-ene-3. 20-dione
9α. 11α-difluoro-21-hydroxypregn-4-ene-3. 20-dione
6α-broιo-9α-fluoro-21-hydroxypregn-4-ene-3, 20-dione9α -fluoro-21-hydroxy-6--eethylpregn-4-ene-3, 20-dione 21-hydroxy-6α -methylpregn-4-ene-3. 20-dione
21-hydroxy-16α-eethylpregn-4-ene-3. 20-dione 6α, 21-dihydroxypregn-4-ene-3. 20-dione
11 α, 21-dihydroxypregn-4-ene-3.20-dione (corticosterone)6α-fluoro-11α. 21-dihydroxypregn-4-ene-3. 20-dione
9α-fluoro-11α, 21-dihydroxypregn-4-ene-3. 20-dϊone
6α. 9α-di fluoro-11 α. 21-hydroxyρregn-4-ene-3.20-dione 9α-fluoro-6α-methyl-11α, 21-dihydroxyρregn-4-ene-3. 20-dione16α. 21 -dihydroxypregn-4-ene-3, 20-dionee 19. 21 -dihydroxyprcgn-4 ene-3. 20-dione 11 α -acetoxy-21 -hydroxypregn-4-ene-3. 20-dione(cort icosterone 11-acetate ) 11 α -acetox -6α -fluoro-21-hydroxypregn-4-ene-3. 20-dione
11α-acetoxy-6α. 9α-di fluoro-21-hydroxypregn-4-ene-3. 20-dione
11α-acetoxy-6- -broB0-9α -fluoro-21-hydroxypregn-4-ene-3, 20-dione 7α-mercapto-21-hydroxypregn-4-ene-3. 20-dione
7α-acetylthio-21-hydroxyρregn-4-ene-3. 20-dione 6α-cyano-21-hydroxypregn-4-ene-3, 20-dione
16α-cyano-21-hydroxypregn-4-ene-3. 20-dione 6α-amino-21-hydroxypregn-4-ene-3,20-dione
16α-amino-21-hydroxypregn-4-ene-3,20-dione 21-hydroxypregna-1.4-diene-3,20-dione
9α-fluoro-21-hydroxypregna-1,4-diene-3,20-dione
21-hydroxypregna-4.6-diene-3,20-dione
9α-fluoro-21-hydroxypregna-4,6-diene-3,20-dione
21-hydroxypregna-4.9(11)-diene-3,20-dione 21-hydroxypregn-4-ene-3,6.20-trione
21-hydroxyρregn-4-ene-3.11.20-trione 21-hydroxypregna-1,4.6-trien-3,20-dione
9α-fluoro-21-hydroxypregna-1.4.6-trien-3,20-dione 21-hydroxy-3-Bethoxypregna-3,5-dien-20-one
9α-fluoro-21-hydroxy-3-methoxypregna-3.5~dien-20-one 21-acetoxypregn-4-ene-3,20-dione (11-desoxycorticosterone 21-acetate)21-acetoxy-2α-fluoropregn-4-ene-3,20-dione
21-acetoxy-4-fluoropregn-4-ene-3,20-dione
21-acetoxy-6α-fluoroaregn-4-ene-3,20-dione 21-acetoxy-9α-broaopregn-4-ene-3,20-dione
21-acetoxy-9α-fluoropregn-4-ene-3,20-dione
21-acetoxy-11α-fluoropregn-4-ene-3,20-dione
21-acetoxy-19-fluoropregn-4-ene-3,20-dione
21-acetoxy-6α,9α-difluoropregn-4-ene-3,20-dione
21-acetoxy-9α.11α-difluoropregn-4-ene-3,20-dione
21-acetoxy-6α-bromo-9α-fluoropregn-4-ene-3,20-dione
21-acetoxy-9α-fluoro-6α-eethylpregn-4-ene-3,20-dione
21-acetoxy-6α-nethylpregn-4-ene-3,20-dione 21-acetoxy-6α-hydroxypregn-4-ene-3. 20-dione
21-acetoxy-11α-hydroxypregn-4-ene-3,20-dione(corticosterone 21-acetate)21-acetoxy-6α-fluoro-11α-hydroxypregn-4-ene-3,20-dione
21-acetoxy-9α-fluoro-11α-hydroxypregn-4-ene-3,20-dione
21-acetoxy-6α,9α-difluoro-11α-hydroxypregn-4-ene-3,20-dione
21-acetoxy-9α-fluoro-6α-methylpregn-4-ene-3,20-dione
21-acetoxy-16β-hydroxypregn-4-ene-3,20-dione
21-acetoxy-7α-acetylthiopregn-4-ene-3,20-dione 21-acetoxy-6α-cyanopregn-4-ene-3,20-dione
21-acetoxy-6α-aBinopregn-4-ene-3,20-dione
21-acetoxypregna-1,4-diene-3,20-dione
21-acetoxy-9α-fluoropregna-1.4-diene-3,20-dione
21-acetoxypregna-4,6-diene-3,20-dione
21-acetoxy-9α-fluoropregna-4,6-diene-3,20-dione
21-acetoxypregna-4.9(11)-diene-3,20-dione 21-acetoxypregn-4-ene-3.6,20-trione
21-acetoxypregn-4-ene-3.9(11).20-trione 21-acetoxypregna-1,4,6-triene-3,20-dione
21-acetoxy-9α-fiuoropregna-1,4.6-triene-3,20-dione
21-acetoxypregna-1,4,9(11)-triene-3,20-dione 21-acetoxy-3-methoxypregna-3,5-dien-20-one 21-acetoxy-6α-fluoro-3-methoxypregna-3,5'dien-20-one 21-hydroxypregn-4-ene-3,20-dione 21-glucuronide(11-desoxycorticosterone 21-glucuronide)
4-fluoro-21-hydroxypregn-4-ene-3,20-dione 21-glucuronide
6α-fluoro-21-hydroxypregn-4-ene-3,20-dione 21-glucuronide
6β-fluoro-21-hydroxypregn-4-ene-3,20-dione 21-glucuronide
9α-chloro-21-hydroxypregn-4-ene-3,20-dione 21-glucuronide
9α-broio-21-hydroxypregn-4-ene-3,20-dione 21-glucuronide
9--fluoro-21-hydroxypregn-4-ene-3,20-dione 21-glucuronide
11α-bronιo-21-hydroxypregn-4-ene-3,20-dione 2l-glucuronide
11α-fluoro-21-hydroxypregn-4-ene-3,20-dione 21-glucuronide
12α-fluoro-21-hydroxypregn-4-ene-3,20-dione 21-glucuronide
16α-fluoro-21-hydroxypregn-4-ene-3,20-dione 21~glucuronide 6α,9f-difluoro-21-hydroxypregn-4-ene-3,20-dione 21-glucuronide
9α.11αdifluoro-21-hydroxypregn-4-ene-3,20-dione 21-glucuronide
6α-bromo-9α-fluoro-21-hydroxypregn-4-ene-3,20-dione 21-glucuronide9α-fluoro-21-hydroxy-6α-aethylpregn-4-ene-3,20-dione 21-glucuronide 21-hydroxy-6α-Bethylpregn-4-ene-3,20-dione 21-glucuronide 11α,21-dihydroxypregn-4-ene-3,20-dione 21-glucuronide (corticosterone 21-glucuronide)
6α-fluoro-11α,21-dihydroxypregn-4-ene-3,20-dione 21-glucuronide9α-fluoro-11α,21-dihydroxypregn-4-ene-3,20-dione 21-glucuronide6α,9α-difluoro-11α,21-hydroxypregn-4-ene-3,20-dione 21-glucuronide9α-fluoro-6α-Bethyl-11α,21-dihydroxypregn-4-ene-3,20-dione 21-glucuro¬nide
11α-acetoxy-21-hydroxypregn-4-ene-3,20-dione 21-glucuronide(corticost¬erone 11-acetate 21-glucuronide)
11α-acetoxy-6α-fluoro-21-hydroxypregn-4-ene-3,20-dione 21-glucuronide11α-acetoxy-6α,9α-difluoro-21-hydroxypregn-4-ene-3,20-dione 21-glucu¬ronide 11α-acetoxy-6α-bromo-9α-fluoro-21-hydroxypregn-4-ene-3,20-dione 21-glucuronide 7α-acetylthio-21-hydroxypregn-4-ene-3,20-dione 21-glucuronide 6α-cyano-21-hydroxypregn-4-ene-3,20-dione 21-glucuronide 21-glucuroni¬de
6α-acetylamino-21-hydroxypregn-4-ene-3,20-dione 21-glucuronide 21-hydroxypregna-1,4-diene-3,20-dione 21-glucuronide
9α-fluoro-21-hydroxypregna-1,4-diene-3,20-dione 21-glucuronide21-hydroxypregna-4.6-diene-3,20-dione 21-glucuronide
9α-fluoro-21-hydroxypregna-4,6-diene-3,20-dione 21-glucuronide21-hydroxypregna-4,9(11)-diene-3,20-dione 21-glucuronide 21-hydroxypregn-4-ene-3,6,20-trione 21-glucuronide
21-hydroxypregn-4-ene-3,11.20-trione 21-glucuronide 21-hydroxypregna-1,4,6-triene-3,20-dione 21-glucuronide
9α-fluoro-21-hydroxypregna-1,4,6-triene-3,20-dione 21-glucuronide 21-hydroxy-3-methoxypregna-3.5-dien-20-one 21-glucuronide
3α,21-dihydroxy-5β-pregnan-20-one
3β.21-dihydroxy-5β-pregnan-20-one
3α,21-dihydroxy-5α-pregnan-20-one
3β.21-dihydroxy-5α-pregnan-20-one
6α-fluoro-3α,21-dihydroxy-5β-pregnan-20-one 6β-fluoro-3α,21-dihydroxy-5β-pregnan-20-one 6α-bromo-3α,21_dihydroxy-5β-pregnan-20-one 9α-fluoro-3α,21-dihydroxy-5β-pregnan-20-one 9α-fluoro-3α,21-dihydroxy-5α-pregnan-20-one 9α-fluoro-3β,21-dihydroxy-5α-pregnan-20-one 9α-fluoro-3β,21-dihydroxy-5β-pregnan-20-one 11α-fluoro-3α,21-dihydroxy-5β-pregnan-20-one 11α-fluoro-3α,21-dihydroxy-5α-pregnan-20-one 11α-fluoro-3β,21-dihydroxy-5α-pregnan-20-one 11α-fluoro-3β,21-dihydroxy-5β-pregnan-20-one 11α-broιao-3α,21-dihydroxy-5β-pregnan-20-one 12α-fluoro-3α,21-dihydroxy-5β-pregnan-20-one 16β-chloro-3α,21-dihydroxy-5β-ρregnan-20-one 16α-fluoro-3α,21-dihydroxy-5β-pregnan-20-one 3α,21-dihydroxy-6α-aethyl-5β-pregnan-20-one 3α,6a,21-trihydroxy-5β-pregnan-20-one3α,6β,21-trihydroxy-5α-pregnan-20-one3α,19,21-trihydroxy-5ββpregnan-20-one 3α,21-dihydroxy-6α-cyano-5p-ppregnan-20-one 3α,21-dihydroxypregn-5(6)-en-20-one
3β,21-dihydroxypregn-5(6)-en-20-one 3α, 11 α, 21 -trihydroxy-5β-pregnan-20-one 3β. 11α, 21-trihydroxy-5β-pregnan-20-one 3α. 11 α, 21-trihydroxy-5α-pregnan-20-one3β, 11α, 21 -trihydroxy-5α-pregnan-20-one 6α-fiuoro-3α,11α,21-trihydroxy-5β-pregnan-20-one
9α-fluoro-3α,11α,21-trihydroxy-5β-pregnan-20-one
9α-fluoro-3α,11α,21-trihydroxy-5α-pregnan-20-one
9α-fluoro-3β,11α,21-trihydroxy-5α-pregnan-20-one
9α-fluoro-3β,11α,21-trihydroxy-5β-pregnan-20-one 3α,21-dihydroxy-5β-pregnane-11,20-dione
3β,21-dihydroxy-5β-pregnane-11,20-dione
3α,21-dihydroxy-5α-pregnane-11,20-dione
3β,21-dihydroxy-5α-pregnane-11.20-dione
6α-fluoro-3α,21-dihydroxy-5β-pregnane-11,20-dione
6β-fluoro-3α,21-dihydroxy-5β-pregnane-11,20-dione
6α-bromo-3α,21-dϊhydroxy-5β-pregnane-11,20-dione
9α-fluoro-3α.21-dihydroxy-5β-pregnane-11,20-dione
9α-fluoro-3α,21-dihydroxy-5α-pregnane-11,20-dione
9α-fluoro-3β,21-dihydroxy-5α-pregnane-11,20-dione
9α-fluoro-3β,21-dihydroxy-5β-pregnane-11,20-dione 3α,21-dιhydroxy-6α-methyl-5β-pregnan-11,20-dione
3α,6a,21-trihydroxy-5β-pregnan-11,20-dione
3β,60,21-trihydroxy-5α-pregnan-11,20-dione 3α,21-dihydroxy-6α-cyano-5β-ppregnan-11,20-dione 3α,21-dihydroxypregn-5(6)-en-11,20-dione
3β,21-dihydroxypregn-5(6)-en-11,20-dione 3α,21-dihydroxy-5β-pregnan-20-one 3α,21-diglucuronide
3β,21-dihydroxy-5β-pregnan-20-one 3β,21-diglucuronide
3α,21-dihydroxy-5α-pregnan-20-one 3α,21-diglucuronide
3β,21-dihydroxy-5α-pregnan-20-one 3β,21-diglucuronide
6α-fluoro-3α,21-dihydroxy-5β-pregnan-20-one 3α,21-diglucuronide6β-fluoro-3α,21-dihydroxy-5β-pregnan-20-one 3α,21-diglucuronide6α-bromo-3α,21-dihydroxy-5β-pregnan-20-one 3α,21-diglucuronide9α-fluoro-3α,21-dihydroxy-5β-pregnan-20-one 3α,21-diglucuronide 9α-fluoro-3α,21-dihydroxy-5α-pregnan-20-one 3α,2l-diglucuronide 9α-fluoro-3β,21-dihydroxy-5α-pregnan-20-one 3β,21-diglucuronide 9α-fluoro-3β,21-dihydroxy-5β-pregnan-20-one β,21-diglucuronide 11α-fluoro-3α,21-dihydroxy-5β-pregnan-20-one3α,21-diglucuronide 11α-fluoro-3α,21-dihydroxy-5α-pregnan-20-one 3α,21-diglucuronide 11α-fluoro-3β,21-dihydroxy-5α-pregnan-20-one3β ,21-diglucuronide 11α-fluoro-3β,21-dihydroxy-5β-pregnan-20-one3β ,21-diglucuronide 12α-fluoro-3α,21-dihydroxy-5β-pregnan-20-one 3α,21-diglucuronide 3α,21-dihydroxy-6e-nethyl-5β-pregnan-20-one 3α,21-diglucuronide 3α,6β,21-trihydroxy-5β-pregnan-20-one 3α.6α,21-triglucuronide 3α,21-dihydroxypregn-5(6)-en-20-one 3α,21-diglucuronide
3β.21-dihydroxypregn-5(6)-en-20-one 3β,21-diglucuronide 3α,11α,21-trihydroxy-5β-pregnan-20-one 3α,21-diglucuronide
3β.11α,21-trihydroxy-5β-pregnan-20-one 3β,21-diglucuronide
3α,11α,21-trihydroxy-5α-pregnan-20-one 3α,21-diglucuronide
3β.11α,21-trihydroxy-5α-pregnan-20-one 3α,21-diglucuronide
6α-fluoro-3α,11α,21-tr hydroxy-5β-pregnan-20-one 3α-,21-diglucuronide 9α-fluoro-3α,11α,21-tr hydroxy-5β-pregnan-20-one 3α,21-diglucuronide 9α-fluoro-3α,11α,21-tr hydroxy-5α-pregnan-20-one 3α,21-diglucuronide9α-fluoro-3β.11α,21-tr hydroxy-5α-pregnan-20-one 3β,21-diglucuronide 9α-fluoro-3β,11α,21-trihydroxy-5β-pregnan-20-one 3β,21-diglucuronide 3α,21-dihydroxy-5β-pregnane-11,20-dione 3α,21-diglucuronide 6α-fluoro-3α,21-dihydroxy-5β-pregnane-11,20-dione 3α,21-diglucuronide9α-fluoro-3α,21-dihydroxy-5β-pregnane-11,20-dione 3α,21-diglucuronide9α-fluoro-3α,21-dihydroxy-5α-pregnane-11,20-dione 3α,21-diglucuronide9α-fluoro-3β,21-dihydroxy-5α-pregnane-11,20-dione 3β.21-diglucuronide9α-fluoro-3β,21-dihydroxy-5β-pregnane-11,20-dione 3β,21-diglucuronide 3α,21-dihydroxy-6α-Bethyl-5β-pregnan-11,20-dione 3α,21-diglucuronide 3α,21-dihydroxypregn-5(6)-en-11,20-dione 3α,21-diglucuronϊde 3β.21-dihydroxypregn-5(6)-en-11,20-dione3β ,21-diglucuronide 3α,21-dihydroxy-5β-pregnan-20-one 3α-glucuronide
3β,21-dihydroxy-5β-pregnan-20-one 3β-giucuronide
3α,21-dihydroxy-5α-pregnan-20-one 3α-glucuronide
3β,21-dihydroxy-5α-pregnan-20-one 3β-glucuronide
6α-fluoro-3α,21-dihydroxy-5β-pregnan-20-one 3α-glucuronide6β-fluoro-3α.21-dihydroxy-5β-pregnan-20-one 3α-glucuronide6α-bromo-3α,21-dihydroxy-50-pregnan-20-one 3α-glucuronide9α-fluoro-3α,21-dihydroxy-50-pregnan-20-one 3α-glucuronide9α-fluoro-3α,21-dihydroxy-5e-pregnan-20-one 3α-glucuronide9α-fluoro-3β,21-dihydroxy-5β-pregnan-20-one 3β-glucuronide9α-fluoro-3β,21-dihydroxy-50-pregnan-20-one 3β-glucuronide11α-fluoro-3α,21-dihydroxy-50-pregnan-20-one 3α-glucuronide11α-fluoro-3α,21-dihydroxy-5β-pregnan-20-one 3α-glucuronide11α-fluoro-3β,21-dihydroxy-5β-pregnan-20-one 3β-glucuronide11α-fluoro-3β,21-dihydroxy-50-pregnan-20-one 3β-glucuronide12β-fluoro-3α,21-dihydroxy-50-pregnan-20-one 3α-glucuronide 3α,21-dihydroxy-6α-methyl-5β-pregnan-20-one 3α-glucuronide 3α,6α,21-trihydroxy-5β-pregnan-20-one 3α-glucuronide 3α,21-dihydroxypregn-5(6)-en-20-one 3α-glucuronide
3β,21-dihydroxypregn-5(6)-en-20-one 3β-glucuronide 3α,11α,21-trihydroxy-50-pregnan-20-one 3α-glucuronide
3β,11α,21-trihydroxy-5β-pregnan-20-one 3β-glucuronide
3α,11α,21-trihydroxy-5β-pregnan-20-one 3α-glucuronide
3β,11α.21-trihydroxy-5β-pregnan-20-one 3α-glucuronide
6α-fluoro-3α,11α,21-trihydroxy-5β-pregnan-20-one 3α-glucuronide9α-fluoro-3α,11α,21-trihydroxy-5β-pregnan-20-one 3α-glucuronide9α-fluoro-3α,11α,21-trihydroxy-5α-pregnan-20-one 3α-glucuronide 9α-fluoro-3β,11α,21-trihydroxy-5α-pregnan-20-one 3β-glucuronide 9α-fluoro-3β,11α,21-trihydroxy-5β-pregnan-20-one 3β-glucuronide 3α,21-dihydroxy-5β-pregnane-11,20-dione 3α-glucuronide 6α-fluoro-3α,21-dihydroxy-5β-pregnane-11,20~dione 3α-glucuronide9α-fluoro-3α,21-dihydroxy-5β-pregnane-11,20-dione 3α-glucuronide9α-fluoro-3α,21-dihydroxy-5α-pregnane-11,20-dione 3α-glucuronide9α-fluoro-3β,21-dihydroxy-5α-pregnane-11.20-dione 3β-glucuronide9α-fluoro-3β,21-dihydroxy-5β-pregnane-11,20-dione 3β-glucuronide 3α,21-dihydroxy-6α-methyl-5β-pregnan-11,20-dione 3α-glucuronide 3α,21-dihydroxypregn-5(6)-en-11,20-dione 3α-glucuronide
3β,21-dihydroxypregn-5(6)-en-11,20-dione 3β-glucuronide
3α,21-dihydroxy-5β-pregnan-20-one 21-glucuronide
3β.21-dihydroxy-5β-pregnan-20-one 21-glucuronide
3α,21-dihydroxy-5α-pregnan-20-one 21-glucuronide
3β,21-dihydroxy-5α-pregnan-20-one 21-glucuronide
6α-fluoro-3α.21-dihydroxy-5β-pregnan-20-one 21-glucuronide6β-fluoro-3α,21-dihydroxy-5β-pregnan-20-one 21-glucuronide6α-bromo-3α,21-dihydroxy-5β-pregnan-20-one 21-glucuronide9α-fluoro-3α,21-dihydroxy-5β-ρregnan-20-one 21-glucuronide9α-fluoro-3α,21-dihydroxy-5α-pregnan-20-one 21-glucuronide9α-fluoro-3β,21-dihydroxy-5α-pregnan-20-one 21-glucuronide9α-fluoro-3β,21-dihydroxy-5β-pregnan-20-one 21-glucuronide11α-fluoro-3α,2I-dihydroxy-5β-pregnan-20-one 21-glucuronide11α-fluoro-3α,21-dihydroxy-5α-pregnan-20-one 21-glucuronide11α-fluoro-3β.21-dihydroxy-5α-pregnan-20-one 21-glucuronide11α-fluoro-3β.21-dihydroxy-5β-pregnan-20-one 21-glucuronide12α-fluoro-3α.21-dihydroxy-5β-pregnan-20-one 21-glucuronide 3α,21-dihydroxy-6α-aethyl-5β-pregnan-20-one 21-glucuronide 3α,6α,21-trihydroxy-50-pregnan-20-one 21-glucuronide 3α,21-dihydroxypregn-5(6)-en-20-one 21-glucuronide
3β.21-dihydroxypregn-5(6)-en-20-one 21-glucuronide 3α,11α,21-trihydroxy-5β-pregnan-20-one 21-glucuronide
3β.11 α,21-trihydroxy-5β-pregnan-20-one 21-glucuronide
3α,11α,21-trihydroxy-5α-pregnan-20-one 21-glucuronide
3β,11α,21-trihydroxy-5α-pregnan-20-one 21-glucuronide
6α-fluoro-3α11 α.21-trihydroxy-5β-pregnan-20-one 21-glucuronide9α-fluoro-3α,11α,21-trihydroxy-5β-pregnan-20-one 21-glucuronide9α-fluoro-3α,11α,21-trihydroxy-5α-pregnan-20-one 21-glucuronide9α-fluoro-3β,11α,21-trihydroxy-5α-pregnan-20-one 21-glucuronide9α-fluoro-3β,11α.21-trihydroxy-5β-pregnan-20-one 21-glucuronide 3α,21-dihydroxy-5β-pregnane-11,20-dione 21-glucuronide 6α-fluoro-3α,21-dihydroxy-50-pregnane-11,20-dione 21-glucuronide 9α-fluoro-3α,21-dihydroxy-50-pregnane-11,20-dione 21-glucuronide 9α-fluoro-3α,21-dihydroxy-5a-pregnane-11,20-dione 21-glucuronide 9α-fluoro-3β,21-dihydroxy-5β-pregnane-11,20-dione 21-glucuronide 9α-fluoro-3β,21-dihydroxy-50-pregnane-11,20-dione 21-glucuronide 3α.21-dihydroxy-6β-Bethyl-5β-pregnane-11,20-dione 21-glucuronide 3α ,21-dihydroxypregn-5(6)-ene-11,20-dione 21-glucuronide
3β ,21-dihydroxypregn-5(6)-ene-11,20-dione 21-glucuronide 3α -acetoxy-21-hydroxy-5β-pregnan-20-one 21-glucuronide
3β-acetoxy-21-hydroxy-5β-pregnan-20-one 21-glucuronide
3α-acetoxy-21-hydroxy-5α-pregnan-20-one 21-glucuronide
3β-acetoxy-21-hydroxy-5α-pregnan-20-one 21-glucuronide
3α-acetoxy-6α-fluoro-21-hydroxy-5β-pregnan-20-one 21-glucuronide3α-acetoxy-6β-fluoro-21-hydroxy-5β-pregnan-20-one 21-glucuronide3α-acetoxy-6α-bromo-21-hydroxy-5β-pregnan-20-one 21-glucuronide3α-acetoxy-9α-fluoro-21-hydroxy-5β-pregnan-20-one 21-glucuronide3α-acetoxy-9α-fluoro-21-hydroxy-5α-pregnan-20-one 21-glucuronide 3β-acetoxy-9α-fluoro-21-hydroxy-5α-pregnan-20-one 21-glucuronide 3β-acetoxy-9α-fluoro-21-hydroxy-5β-pregnan-20-one 21-glucuronide3α-acetoxy-11α-fluoro-21-hydroxy-5β-pregnan-20-one 21-glucuronide3α-acetoxy-11α-fluoro-21-hydroxy-5α-pregnan-20-one 21-glucuronide3β-acetoxy-11α-fluoro-21-hydroxy-5α-pregnan-20-one 21-glucuronide3β-acetoxy-11α-fluoro-21-hydroxy-5β-pregnan-20-one 21-glucuronide3α-acetoxy-12α-fluoro-21-hydroxy-5β-pregnan-20-one 21-glucuronide3α,6α-diacetoxy-21-hydroxy-5β-pregnan-20-one 21-glucuronide 3α-acetoxy-21-hydroxypregn-5(6)-en-20-one 21-glucuronide
3β-acetoxy-21-hydroxypregn-5(6)-en-20-one 21-glucuronide 3α,11α-diacetoxy-21-hydroxy-5β-pregnan-20-one 21-glucuronide 3β,11α-diacetoxy-21-hydroxy-5β-pregnan-20-one 21-glucuronide 3α,11α-diacetoxy-21-hydroxy-5α-pregnan-20-one 21-glucuronide
3α,11α-diacetoxy-21-hydroxy-5α-pregnan-20-one 21-gIucuronide
3α,11α-diacetoxy-6α-fluoro-21-hydroxy-5β-pregnan-20-one 21-glucuronide3α,11α-diacetoxy-9α-fluoro-21-hydroxy-5β-pregnan-20-one 21-glucuronide3α,11α-diacetoxy-9α-fluoro-21-hydroxy-5α-pregnan-20-one 21-glucuronide 3β,11α-diacetoxy-9α-fluoro-21-hydroxy-5α-pregnan-20-one 21-glucuronide 3β,11α-diacetoxy-9α-fluoro-21-hydroxy-5β-pregnan-20-one 21-glucuronide 3α-acetoxy-21-hydroxy-5β-pregnane-11,20-dione 21-glucuronide
3α-acetoxy-6α-fluoro-21-hydroxy-5β-pregnane-11,20-dione 21-gIucuronide 3α-acetoxy-9α-fluoro-21-hydroxy-5β-pregnane-11,20-dione 21-glucuronide 3α-acetoxy-9α-fluoro-21-hydroxy-5α-pregnane-11,20-dione 21-glucuronide3β-acetoxy-9α-fluoro-21-hydroxy-5β-pregnane-11,20-dione 21-glucuronide3β-acetoxy-9α-fluoro-21-hydroxy-5β-pregnane-11,20-dione 21-glucuronide 3α-acetoxy-21-hydroxy-6α-nethyl-5β-pregnane-11,20-dione 21-glucuronide3α-acetoxy-21-hydroxypregn-5(6)-ene-11,20-dione 21-glucuronide 3β-acetoxy-21-hydroxypregn-5(6)-ene-11.20-dione 21-glucuronide3α-acetoxy-21-hydroxy-5β-pregnan-20-one
3β-acetoxy-21-hydroxy-5β-pregnan-20-one
3α-acetoxy-21-hydroxy-5α-pregnan-20-one
3β-acetoxy-21-hydroxy-5α-pregnan-20-one
3α-acetoxy-6α-fluoro-21-hydroxy-5β-pregnan-20-one
3α-acetoxy-6α-fluoro-21-hydroxy-5β-pregnan-20-one
3α-acetoxy-6β-broao-21-hydroxy-5β-pregrian-20-one
3α-acetoxy-9α-fluoro-21-hydroxy-5β-pregnan-20-one
3α-acetoxy-9α-fluoro-21-hydroxy-5α-pregnan-20-one
3β-acetoxy-9α-fluoro-21-hydroxy-5α-pregnan-20-one
3β-acetoxy-9α-fluoro-21-hydroxy-5β-pregnan-20-one
3α-acetoxy-11α-fluoro-21-hydroxy-5β-pregnan-20-one
3α-acetoxy-11α-fluoro-21-hydroxy-5α-pregnan-20-one
3β-acetoxy-11α-fluoro-21-hydroxy-5α-pregnan-20-one
3β-acetoxy-11α-fluoro-21-hydroxy-5β-pregnan-20-one 3α-acetoxy-12α-f luoro-21-hydroxy-5β-pregnan-20-one
3α, 6α-diaeetoxy-21-hydroxy-5β-pregnan-20-one
3α -acetoxy-21-hydroxypregn-5(6)-en-20-one
3β-acetoxy-21-hydroxypregn-5(6)-en-20-one
3α,11α-diacetoxy-21-hydroxy-5β-pregnan-20-one
3β,11α-diacetoxy-21-hydroxy-5β-pregnan-20-one
3α,11α-diacetoxy-21-hydroxy-5α-pregnan-20-one
3α,11α-diacetoxy-21-hydroxy-5α-pregnan-20-one
3α,11α-diacetoxy-6α-fluoro-21-hydroxy-5β-pregnan-20-one
3α,11α-diacetoxy-9α-fluoro-21-hydroxy-5α-pregnan-20-one
3β,11α-diacetoxy-9α-fluoro-21-hydroxy-5β-pregnan-20-one
3α-acetoxy-21-hydroxy-50-pregnane-11,20-dione
3α-acetoxy-6α-fluoro-21-hydroxy-5β-pregnane-11,20-dione
3α-acetoxy-9α-fluoro-21-hydroxy-5β-pregnane-11,20-dione
3α-acetoxy-9α-fluoro-21-hydroxy-5α-pregnane-11,20-dione
3β-acetoxy-9α-fluoro-21-hydroxy-5α-pregnane-11,20-dione
3β-acetoxy-9α-fluoro-21-hydroxy-5β-pregnane-11,20-dione
3α-acetoxy-21-hydroxy-6α-Bethyl-5β-pregnane-11,20-dione
3α-acetoxy-21-hydroxypregn-5(6)-ene-11,20-dione
3β-acetoxy-21-hydroxypregn-5(6)-ene-14,20-dione 21-acetoxy-3α-hydroxy-5β-pregnan-20-one3α-glucuronide
21-acetoxy-3β-hydroxy-5β-pregnan-20-one 3β-glucuronide
21-acetoxy-3α-hydroxy-5α-pregnan-20-one 3α-glucuronide
21-acetoxy-3β-hydroxy-5α-pregnan-20-one 3β-glucuronide
21-acetoxy-6α-fluoro-3α-hydroxy-5β-pregnan-20-one 3α-glucuronide21-acetoxy-6β-fluoro-3α-hydroxy-5β-pregnan-20-one 3α-glucuronide21-acetoxy-6α-bromo-3α-hydroxy-5β-pregnan-20-one3α-glucuronide21-acetoxy-9α-fluoro-3α-hydroxy-5β-pregnan-20-one 3α-glucuronide21-acetoxy-9α-fluoro-3α-hydroxy-5α-pregnan-20-one 3α-glucuronide21-acetoxy-9α-fluoro-3β-hydroxy-5α-pregnan-20-one 3β-glucuronide21-acetoxy-9α-fluoro-3β-hydroxy-5β-pregnan-20-one 3β-glucuronide21-acetoxy-11α-fluoro-3α-hydroxy-5β-pregnan-20-one 3α-glucuronide21-acetoxy-11α-fluoro-3α-hydroxy-5α-pregnan-20-one 3α-glucuronide21-acetoxy-11α-fluoro-3β-hydroxy-5α-pregnan-20-one 3β-glucuronide 21-acetoxy-11α-fluoro-3β-hydroxy-5β-pregnan-20-one 3β-glucuronide21-acetoxy-12α-fluoro-3α-hydroxy-5β-pregnan-20-one 3α-glucuronide6α,21-diacetoxy-3α-hydroxy-5β-pregnan-20-one 3α-glucuronide
21-acetoxy-3α-hydroxypregn-5(6)-en-20-one 3α-glucuronide
21-acetoxy-3β-hydroxypregn-5(6)-en-20-one 3β-glucuronide 11α,21-diacetoxy-3α-hydroxy-5β-ρregnan-20-one 3α-glucuronide
11α,21-diacetoxy-3β-hydroxy-5β-pregnan-20-one 3β-glucuronide
11α.21-diacetoxy-3α-hydroxy-5α-pregnan-20-one 3α-glucuronide
11α,21-diacetoxy-3β-hydroxy-5α-pregnan-20-one 3α-glucuronide
11α,21-diacetoxy-6α-fluoro-3α-hydroxy-5β-pregnan-20-one 3α-glucuronide 11α,21-diacetoxy-9α-fluoro-3α-hydroxy-5β-pregnan-20-one 3α-glucuronide 11α,21-diacetoxy-9α-fluoro-3α-hydroxy-5α-pregnan-20-one 3α-glucuronide11α,21-diacetoxy-9α-fluoro-3β-hydroxy-5α-pregnan-20-one 3β-glucuronide 11α,21-diacetoxy-9α-fluoro-3β-hydroxy-5β-pregnan-20-one 3β-glucuronide 21-acetoxy-3α-hydroxy-5β-ρregnane-11,20-dione 3β-glucuronide
21-acetoxy-6α-fluoro-3α-hydroxy-5β-pregnane-11,20-dione 3α-glucuronide21-acetoxy-9α-fluoro-3α-hydroxy-5β-pregnane-11,20-dione 3α-glucuronide21-acetoxy-9α-fluoro-3α-hydroxy-5α-pregnane-11,20-dione 3α-glucuronide21-acetoxy-9α-fluoro-3β-hydroxy-5α-pregnane-11,20-dione 3β-glucuronide21-acetoxy-9α-fluoro-3β-hydroxy-5β-pregnane-11,20-dione 3β-glucuronide 21-acetoxy-3α-hydroxy-6α-methyl-5β-pregnane-11,20-dione 3α-glucuronide21-acetoxy-3α-hydroxypregn-5(6)-ene-11,20-dione 3α-glucuronide
21-acetoxy-3β-hydroxypregn-5(6)-ene-11,20-dione 3β-glucuronide
21 -hydroxy-5β -pregnane-3, 20-dione
21-hydroxy-5α-pregnane-3. 20-dione
6α-fIuoro-21-hydroxy-5β-pregnane-3,20-dione 6β-fluoro-21-hydroxy-5β-pregnane-3,20-dione6α-bromo-21-hydroxy-5β-pregnane-3,20-dione9α-fluoτo-21-hydroxy-5β-pregnane-3,20-dione9α-fluoro-21-hydroxy-5α-pregnane-3,20-dione9α-fluoro-21-hydroxy-5β-pregnane-3,20-dione11α-fluoro-21-hydroxy-5α-pregnane-3,20-dione11α-fluoro-21-hydroxy-5β-pregnane-3,20-dione11α-bromo-21-hydroxy-5β-pregnane-3,20-dione12α-fluoro-21-hydroxy-5β-ρregnane-3,20-dione16β-chloro-21-hydroxy-5β-pregnane-3,20-dione16α-fIuoro-21-hydroxy-5β-ρregnane-3,20-dione 21-hydroxy-6α-methyl-5β-pregnane-3,20-dione 6α,21-dihydroxy-5β-pregnane-3,20-dione
6β,21-dihydroxy-5α-pregnane-3,20-dione
19,21-dihydroxy-5β-pregnane-3,20-dione 21-hydroxy-6α-cyano-5β-ppregnane-3,20-dione 21-hydroxypregn-5(6)-ene-3,20-dione
11α,21-dihydroxy-5β-pregnane-3,20-dione
11α,21-dihydroxy-5α-pregnane-3,20-dione
6α-fluoro-11α,21-dihydroxy-5β-pregnane-3,20-dione9α-fluoro-11α,21-dihydroxy-5β-pregnane-3,20-dione9α-fluoro-11α,21-dihydroxy-5α-pregnane-3,20-dione9α-fluoro-11α,21-dihydroxy-5β-pregnane-3,20-dione 21-hydroxy-5β-ρregnane-3,11,20-trione
21-hydroxy-5α-pregnane-3,11,20-trione 6α-fluoro-21-hydroxy-5β-pregnane-3,11,20-trione
6β-fluoro-21-hydroxy-5β-pregnane-3,11,20-trione
6α-bromo-21-hydroxy-5β-pregnane-3,11,20-trione
9α-fluoro-21-hydroxy-5β-pregnane-3,11,20-trione
9α-fluoro-21-hydroxy-5α-pregnane-3,11,20-trione 21-hydroxy-6α-methyl-5β-pregnane-3,11,20-trione
6α.21-dihydroxy-5β-pregnane-3,11,20-trione
6β.21-dihydroxy-5α-pregnane-3,11,20-trione 21-hydroxy-6α-cyano-5β-pregnane-3,11,20-trione 21-hydroxypregn-5(6)-ene-3,11,20-trione 21-hydroxy-5β-pregnane-3.20-dione 21-glucuronide
21-hydroxy-5α-pregnane-3,20-dione 21-glucuronide
6α-fluoro-21-hydroxy-5β-pregnane-3,20-dione 21-glucuronide 6β-fluoro-21-hydroxy-5β-pregnane-3,20-dione 21-glucuronide 6α-bromo-21-hydroxy-5β-pregnane-3,20-dione 21-glucuronide 9α-fluoro-21-hydroxy-5β-pregnane-3,20-dione 21-glucuronide 9α-fluoro-21-hydroxy-5α-pregnane-3,20-dione 21-glucuronide 9α-fluoro-21-hydroxy-5β-ρregnane-3,20-dione 21-glucuronide 11α-fluoro-21-hydroxy-5α-pregnane-3,20-dione 21-glucuronide 11α-fluoro-21-hydroxy-5β-pregnane-3,20-dione 21-glucuronide 12α-fluoro-21-hydroxy-5β-pregnane-3,20-dione 21-glucuronide 21-hydroxy-6α-Bethyl-5β-pregnane-3,20-dione 21-glucuronide 21-hydroxy-6α-cyano-5β-pregnane-3.20-dione 21-glucuronide 21-hydroxypregn-5(6)-ene-3,20-dione 21-glucuronide 11α,2l-dihydroxy-5β-pregnane-3,20-dione 21-glucuronide
11α,21-dihydroxy-5α-pregnane-3,20-dione 21-glucuronide
6α-fluoro-11α,21-dihydroxy-5β-pregnane-3,20-dione 21-glucuronide 9α-fluoro-11α,21-dihydroxy-5β-pregnane-3,20-dione 21-glucuronide 9α fluoro-11α.21-dihydroxy-5α-pregnane-3.20-dione 21-glucuronide 21-hydroxy-5β-pregnane-3,11,20-trione 21-glucuronide
21-hydroxy-5α-pregnane-3,11,20-trione 21-glucuronide
6α-fluoro-21-hydroxy-5β-pregnane-3,11,20-trione 21-glucuronide9α-fluoro-21-hydroxy-5β-pregnane-3.11,20-trione 21-glucuronide9α-fluoro-21-hydroxy-5α-pregnane-3,11,20-trione 2l-glucuronide 21-hydroxy-6α-methyl-5β-pregnane-3,11,20-trione 21-glucuronide 21-hydroxy-6α-cyano-5β-pregnan-3,11,20-trione 21-glucuronide 21-hydroxypregn-5(6)-ene-3,11,20-trione 21-glucuronide 21-acetoxy-5β-pregnane-3,20-dione
21-acetoxy-5α-pregnane-3,20-dione
21-acetoxy-6α-fluoro-5β-pregnane-3,20-dione
21-acetoxy-6β-fluoro-5β-pregnane-3,20-dione
21-acetoxy-6α-broio-5β-pregnane-3,20-dione
21-acetoxy-9α-fluoro-5β-pregnane-3,20-dione
21-acetoxy-9α-fluoro-5α-pregnane-3,20-dione
21-acetoxy-9α-fluoro-5β-pregnane-3,20-dione
21-acetoxy-11α-fluoro-5α-pregnane-3,20-dione
21-acetoxy-11α-flύoro-5β-pregnane-3.20-dione
21-acetoxy-11α-bromo-5β-pregnane-3.20-dione
21-acetoxy-12α-fluoro-5β-pregnane-3, 20-dione
21-acetoxy-16β-chloro-5β-pregnane-3, 20-dtone
21-acetoxy-16α-fluoro-5β-pregnane-3, 20-dione 21- acetoxy-6α-Bethyl-5β-pregnane-3, 20-dione 21-acetoxy-6α-cyano-5β-pregnane-3, 20-dione 21-acetoxypregn-5(6)-ene-3, 20-dione 11α,21-diacetoxy-5β-pregnane-3.20-dione
11α,21-diacetoxy-5α-pregnane-3.20-dione
21-acetoxy-6α-fluoro-11α-hydroxy-5β-pregnane-3,20-dione 21-acetoxy-9α-fluoro-11α-hydroxy-5β-pregnane-3,20-dione21-acetoxy-9α-fluoro-11α-hydroxy-5α-pregnane-3.20-dione 21-acetoxy-9α-fluoro-11α-hydroxy-5β-ρregnane-3,20-dione 21-acetoxy-5β-pregnane-3.11.20-trione
21-acetoxy-5α-pregnane-3.11.20-trione
21-acetoxy-6α-fluoro-5β-ρregnane-3,11,20-trione
21-acetoxy-6β-fluoro-5β-pregnane-3,11,20-trione
21-acetoxy-6α-bromo-5β-pregnane-3,11,20-trione
21-acetoxy-9α-fluoro-5β-pregnane-3,11,20-trione
21-acetoxy-9α-fluoro-5α-pregnane-3,11,20-trione 21-acetoxy-6α-methyl-5β-pregnane-3.11.20-trione
6α,21-diacetoxy-5β-pregnane-3,11,20-trione
6β,21-diacetoxy-5α-pregnane-3,11,20-trione 21-acetoxy-6α-cyano-5β-pregnane-3,11,20-trione 21-acetoxypregn-5(6)-ene-3,11,20-trione
21 -hydroxy-19-norpregn-4-one-3, 20-dione (11 -desoxy-19-norcorticostero¬ne)
4-f luoro-21-hydroxy-19-norpregn-4-ene-3, 20-dione
6α-fluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione
9α-fluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione
11α-fluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione
6α.9α-difluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione
9α,11α-difluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione
6α-bromo-9α-fluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione
9α-fluoro-21-hydroxy-6α-Bethyl-19-norpregn-4-ene-3,20-dione
21-hydroxy-6α-Beιhyl-19-norpregn-4-ene-3,20-dione
11α,21-dihydroxy-19-norpregn-4-ene-3,20-dione (19-norcorticosterone) 6α-fluoro-11α,21-dihydroxy-19-norpregn-4-ene-3,20-dione
9α-fluoro-11α,21-dihydroxy-19-norpregn-4-ene-3,20-dione
6α,9α-difluoro-11α.21-hydroxy-19-norpregn-4-ene-3,20-dione
9α-fluoro-6α-Bethyl-11α,21-dihydroxy-19-norpregn-4-ene-3,20-dϊone 11α-acetoxy-21-hydroxy-19-norpregn-4-ene-3.20-dione (19-norcorticoste¬rone 11-acetate)
11α-acetoxy-6α-fluoro-21-hydroxy-19-norpregn-4-ene-3.20-dione
11α-acetoxy-6α,9α-difluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione11α-acetoxy-6α-bromo-9α-fluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione 21-acetoxy-6α-fluoro-19-norpregn-4-ene-3,20-dione
21-acetoxy-9α-bromo-19-norpregn-4-ene-3,20-dione
21-acetoxy-9α-fluoro-19-norpregn-4-ene-3,20-dione
21-acetoxy-11α-fluoro-19-norpregn-4-ene-3,20-dione
21-acetoxy-19-fluoro-19-norpregn-4-ene-3,20-dione
21-acetoxy-6α, 9α-difluoro-19-norpregn-4-ene-3, 20-dione
2l-acetoxy-9α,11α-difluoro-19-norpregn-4-ene-3, 20-dione
21-acetoxy-6α-broio-9α-fluoro-19-norpregn-4-ene-3, 20-dione
21-acetoxy-9α-fluoro-6β-Bethyl-19-norpregn-4-ene-3, 20-dione
21-acetoxy-6α-methyl-19-norpregn-4-ene-3, 20-dione
21-acetoxy-11α-hydroxy-19-norpregn-4-ene-3. 20-dione (19-norcorticoste¬rone 21-acetate)
21-acetoxy-6α-fluoro-11α-hydroxy-19-norρregn-4-ene-3. 20-dione 21 -acetoxy-9α- fluoro- 11α-hydroxy- 19-norpregn-4 ene-3, 20-dione
21 -acetoxy-6α, 9α-difluoro-11α-hydroxy-19-norpregn-4-ene-3. 20-dione 21-hydroxy-19-norpregn-4-ene-3,20-dione 21-glucuronide (11-desoxy-19- norcorticosterone 21-glucuronide)
4-fluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione 21-glucuronide 6α-fluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione 21-glucuronide 6β-fluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione 21-glucuronide 9α-chloro-21-hydroxy-19-norpregn-4-ene-3,20-dione 21-glucuronide 9α-bromo-21-hydroxy-19-norpregn-4-ene-3,20-dione 21-glucuronide 9α-fluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione 21-glucuronide 11α-bromo-21-hydroxy-19-norpregn-4-ene-3,20-dione 21-glucuronide 11α-fluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione 21-glucuronide 6α,9α-difluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione 21-glucuronide 9α,11α-difluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione 21-glucuronide 6α-broto-9α-fluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione 21-glucuronide
9α-fluoro-21-hydroxy-6α-Bethyl-19-norpregn-4-ene-3,20-dione 21-glucuronide
11α,21-dihydroxy-19-norpregn-4-ene-3.20-dione 21-glucuronide (19-nor-corticosterone 21-glucuronide)
6α-fluoro-11α,21-dihydroxy-19-norpregn-4-ene-3,20-dione 21-glucuronide 9α-fluoro-11α,21-dihydroxy-19-norpregn-4-ene-3,20-dione 21-glucuronide 6α.9α-difluoro-11α,21-hydroxy-19-norpregn-4-ene-3,20-dione 21-glucuro¬nide
9α-fluoro-6α-iethyl-11α,21-dihydroxy-19-norpregn-4-ene-3.20-dione 21-glucuronide
11α-acetoxy-21-hydroxy-19-norpregn-4-ene-3,20-dione 21-glucuronide(corticosterone 11-acetate 21-glucuronide)
11α-acetoxy-6α-fluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione 21-glu¬curonide
11α-acetoxy-6α,9α-difluoro-21-hydroxy-19-norpregn-4-ene-3.20-dione 2-1-glucuronide 11α-acetoxy-6α-bromo-9α-fluoro-21-hydroxy-19-norpregn-4-ene-3,20-dione
21-glucuronide
3α,21-dihydroxy-5β-19-norpregnan-20 one 21-glucuronide
3β,21-dihydroxy-5β-19-norpregnan-20-one 21-glucuronide
3α,21-dihydroxy-5α-19-norpregnan-20-one 21-glucuronide
3β,21-dihydroxy-5α-19-norpregnan-20-one 21-glucuronide
6α-fluoro-3α,21-dihydroxy-5β-19-norpregnan-20-one 21-glucuronide 6β-fluoro-3α,21-dihydroxy-5β-19-norpregnan-20-one 21-glucuronide 6α-bromo-3α,21-dihydroxy-5β-19-norpregnan-20-one 21-glucuronide 9α-fluoro-3α,21-dihydroxy-5β-19-norpregnan-20-one 21-glucuronide 9α-fluoro-3α,21-dihydroxy-5α-19-norpregnan-20-one 21-glucuronide 9α-fluoro-3β,21-dihydroxy-5α-19-norpregnan-20-one 21-glucuronide 9α-fluoro-3β,21-dihydroxy-5β-19-norpregnan-20-one 21-glucuronide 11α-fluoro-3α,21-dihydroxy-5β-19-norpregnan-20-one 21-glucuronide 11α-fluoro-3α,21-dihydroxy-5α-19-norpregnan-20-one 21-glucuronide 11α-fluoro-3β,21-dihydroxy-5α-19-norpregnan-20-one 21-glucuronide 11α-fluoro-3β.21-dihydroxy-5β-19-norpregnan-20-one 21-glucuronide 12α-fluoro-3α,21-dihydroxy-5β-19-norpregnan-20-one 21-glucuronide 3α,21-dihydroxy-6α-methyl-5β-19-norpregnan-20-one 21-glucuronide 3α.6α,21-trihydroxy-5β-19-norpregnan-20-one 21-glucuronide 3α,21-dihydroxy-19-norpregn-5(6)-en-20-one 21-glucuronide
3β,21-dihydroxy-19-norpregn-5(6)-en-20-one 21-glucuronide 3α,11α,21-trihydroxy-5β-19-norpregnan-20-one 21-glucuronide
3β,11α,21-trihydroxy-5β-19-norpregnan-20-one 21-glucuronide
3α,11α.21-trihydroxy-5α-19-norpregnan-20-one 21-glucuronide
3β,11α,21-trihydroxy-5α-19-norpregnan-20-one 21-glucuronide
6α-fluoro-3α,11α,21-trihydroxy-5β-19-norpregnan-20-one 21-glucuronide9α-fluoro-3α,11α,21-trihydroxy-5β-19-norpregnan-20-one 21-glucuronide9α-fluoro-3α,11α.21-trihydroxy-5α-19-norpregnan-20-one 21-glucuronide9α-fluoro-3β,11α,21-trihydroxy-5α-19-norpregnan-20-one 21-glucuronide9α-fluoro-3β,11α.21-trihydroxy-5β-19-norpregnan-20-one 21-glucuronide 3α,21-dihydroxy-5β-19-norpregnane-11,20-dione 21-glucuronide 6α-fluoro-3α,21-dihydroxy-5β-19-norpregnane-11,20-dione 21-glucuronide 9α-fluoro-3α,21-dihydroxy-5β-19-norpregnane-11,20-dione 21-glucuronide 9α-fluoro-3α,21-dihydroxy-5α-19-norpregnane-11,20-dione 21-glucuronide 9α-fluoro-3β,21-dϊhydroxy-5α-19-norpregnane-11,20-dione 21-glucuronide 9α-fluoro-3β,21-dihydroxy-5β-19-norpregnane-11,20-dione 21-glucuronide
3α,21-dihydroxy-6α-methyl-5β-19-norpregnane-11,20-dione 21-glucuronide
3α,21-dihydroxy-19-norpregn-5(6)-ene-11,20-dione21-glucuronide3β,21-dihydroxy-19-norpregn-5(6)-ene-11, 20-dione 21 -glucuronide 3α-acetoxy-21-hydroxy-5β-19-norpregnan-20-one 21-glucuronide
3β-acetoxy-21-hydroxy-5β-l9-norpregnan-20-one21-glucuronide
3α-acetoxy-21-hydroxy-5α-19-norpregnan-20-one 21-glucuronide
3β-acetoxy-21-hydroxy-5α-19-norpregnan-20-one 21-glucuronide
3α-acetoxy-6α-fluoro-21-hydroxy-5β-19-norρregnan-20-one 21-glucuronide 3α-acetoxy-6β-fluoro-21-hydroxy-5β-19-norpregnan-20-one 21-glucuronide 3α-acetoxy-6α-bromo-21-hydroxy-5β-19-norpregnan-20-one 21-glucuronide3α-acetoxy-9α-fluoro-21-hydroxy-5β-19-norpregnan-20-one 21-glucuronide 3α-acetoxy-9α-fluoro-21-hydroxy-5α-19-norpregnan-20-one 21-glucuronide 3β-acetoxy-9α-fluoro-21-hydroxy-5α-19-norpregnan-20-one 21-glucuronide 3β-acetoxy-9α-fluoro-21-hydroxy-5β-19-norpregnan-20-one 21-glucuronide 3α-acetoxy-11α-fluoro-21-hydroxy-5β-19-norpregnan-20-one 21- glucuronide
3α-acetoxy-11α-fluoro-21-hydroxy-5α-19-norpregnan-20-one 21- glucuronide
3β-acetoxy-11α-fluoro-21-hydroxy-5α-19-norpregnan-20-one 21- glucuronide
30-acetoxy-11α-fluoro-21-hydroxy-5β-19-norpregnan-20-one 21- glucuronide
3α-acetoxy-12α-fluoro-21-hydroxy-5β-19-norpregnan-20-one 21- glucuronide
3α,6α-diacetoxy-21-hydroxy-5β-19-norpregnan-20-one 21-glucuronide 3α-acetoxy-21-hydroxy-19-norpregn-5(6)-en-20-one 21-glucuronide 3β-acetoxy-21-hydroxy-19-norpregn-5(6)-en-20-one 21-glucuronide 3α,11α-diacetoxy-21-hydroxy-5β-19-norpregnan-20-one 21-glucuronide3β,11α-diacetoxy-21-hydroxy-5β-l9-norpregnan-20-one 21-glucuronide 3α,11α-diacetoxy-21-hydroxy-5α-19-norρregnan-20-one 21-glucuronide 3α,11α-diacetoxy-21-hydroxy-5α-19-norpregnan-20-one 21-glucuronide 3α,11α-diacetoxy-6α-fluoro-21-hydroxy-5β-19-norpregnan-20-one 21-glucuronide
3α,11α-diacetoxy-9α-fluoro-21-hydroxy-5β-19-norpregnan-20-one 21-glucuronide
3α,11α-diacetoxy-9α-fluoro-21-hydroxy-5α-19-norpregnan-20-one 21-glucuronide
3β,11α-diacetoxy-9α-fluoro-21-hydroxy-5α-19-norpregnan-20-one 21-glucuronide
30,11α-diacetoxy-9α-fluoro-21-hydroxy-5β-19-norpregnan-20-one 21-glucuronide
3α-acetoxy-21-hydroxy-5β-19-norpregnane-11,20-dione 21-glucuronide 3α-acetoxy-6α-fluoro-21-hydroxy-5β-19-norpregnane-11,20-dione 21-glucuronide
3β-acetoxy-9α-fluoro-21-hydroxy-5β-19-norρregnane-11,20-dione 21-glucuronide
3α-acetoxy-9α-fluoro-21-hydroxy-5α-19-norpregnane-11,20 dione 21-glucu ronide
3β-acetoxy-9α-fluoro-21-hydroxy-5α-19-norpregnane-11.20-dione 21-glucuronide
3β-acetoxy-9α-fluoro-21-hydroxy-5β-19-norpregnane-11,20-dione 21-glucuronide
3α-acetoxy-21-hydroxy-6α-methyl-5β-19-norpregnan-11.20-dione 21-glucuronide
3α-acetoxy-21-hydroxy-19-norpregn-5(6)-ene-11,20-dione 21-glucuronide3β-acetoxy-21-hydroxy-19-norpregn-5(6)-ene-11.20-dione 21-glucuronide3α-acetoxy-21-hydroxy-5β-19-norpregnan-20-one
3β-acetoxy-21-hydroxy-5β-19-norpregnan-20-one
3α-acetoxy-21-hydroxy-5α-19-norpregnan-20-one
3β-acetoxy-21-hydroxy-5α-19-norpregnan-20-one
3α-acetoxy-6α-fluoro-21-hydroxy-5β-19-norpregnan-20-one
3α-acetoxy-6β-fluoro-21-hydroxy-5β-19-norpregnan-20-one
3α-acetoxy-6α-broBθ-21-hydroxy-5β-19-norpregnan-20-one
3α-acetoxy-9α-fluoro-21-hydroxy-5β-19-norpregnan-20-one
3α-acetoxy-9α-fluoro-21-hydroxy-5α-19-norpregnan-20-one
3β-acetoxy-9α-fluoro-21-hydroxy-5α-19-norpregnan-20-one
3β-acetoxy-9α-fluoro-21-hydroxy-5β-19-norpregnan-20-one
3α-acetoxy-11α-fiuoro-21-hydroxy-5β-19-norpregnan-20-one
3α-acetoxy-11α-fluoro-21-hydroxy-5α-19-norpregnan-20-one
3β-acetoxy-11α-fluoro-21-hydroxy-5α-19-norpregnan-20-one
3β-acetoxy-11α-fluoro-21-hydroxy-5β-19-norpregnan-20-one
3α-acetoxy-12β-fluoro-21-hydroxy-5β-19-norpregnan-20-one
3α,6α-diacetoxy-21-hydroxy-5β-19-norpregnan-20-one
3α-acetoxy-21-hydroxy-19-norpregn-5(6)-en-20-one
3β-acetoxy-21-hydroxy-19-norpregn-5(6)-en-20-one
3α,11α-diacetoxy-21-hydroxy-5β-19-norpregnan-20-one
3β,11α-diacetoxy-21-hydroxy-5β-19-norpregnan-20-one
3α,11α-diacetoxy-21-hydroxy-5α-19-norpregnan-20-one
3α,11α-diacetoxy-21-hydroxy-5α-19-norpregnan-20-one
3α,11α-diacetoxy-6α-fluoro-21-hydroxy-5β-19-norpregnan-20-one
3α,11α-diacetoxy-9α-fluoro-21-hydroxy-5β-19-norpregnan-20-one
3α,11α-diacetoxy-9α-fluoro-21-hydroxy-5α-199norpregnan-20-one 3β,11α-diacetoxy-9α-fluoro-21-hydroxy-5α-19-norpregnan-20-one 30.11α-diacetoxy-9α-fluoro-21-hydroxy-5β-19-norpregnan-20-one3α-acetoxy-21-hydroxy-50-19-norpregnane-11,20-dione
3α-acetoxy-6α-fluoro-21-hydroxy-5β-19-norpregnane-11,20-dione3α-acetoxy-9α-fluoro-21-hydroxy-5β-19-norpregnane-11,20-dione3α-acetoxy-9α-fluoro-21-hydroxy-5α-19-norpregnane-11,20-dione3β-acetoxy-9α-fluoro-21-hydroxy-5α-19-norρregnane-11,20-dione3β-acetoxy-9α-fluoro-21-hydroxy-5β-19-norpregnane-11,20-dione3α-acetoxy-21-hydroxy-6α-methyl-5β-19-norpregnan-11,20-dione3α-acetoxy-21-hydroxy-19-norpregn-5(6)-ene-11,20-dione3β-acetoxy-21-hydroxy-19-norpregn-5(6)-ene-11,20-dione
21-acetoxy-3α-hydroxy-5β-19-norpregnan-20-one 3α-glucuronide
21-acetoxy-3β-hydroxy-5β-19-norpregnan-20-one 3β-glucuronide
21-acetoxy-3α-hydroxy-5α-19-norpregnan-20-one 3β-glucuronide
21-acetoxy-3β-hydroxy-5α-19-norpregnan-20-one 3β-glucuronide
21-acetoxy-6α-fluoro-3α-hydroxy-5β-19-norpregnan-20-one 3α-glucuronide 21-acetoxy-6β-fluoro-3α-hydroxy-5β-19-norpregnan-20-one 3a-glucuronide 21-acetoxy-6α-bromo-3α-hydroxy-5β-19-norpregnan-20-one 3α-glucuronide21-acetoxy-9α-fluoro-3β-hydroxy-5β-19-norpregnan-20-one 3α-glucuronide 21-acetoxy-9α-fluoro-3α-hydroxy-5α-19-norpregnan-20-one 3α-glucuronide 21-acetoxy-9α-fluoro-3β-hydroxy-5α-19-norpregnan-20-one 3β-glucuronide 21-acetoxy-9α-fluoro-3β-hydroxy-5β-19-norpregnan-20-one 3β-glucuronide 21-acetoxy-11α-f1uoro-3α-hydroxy-5β-19-norpregnan-20-one 3α-glucuronide
21-acetoxy-11α-fluoro-3α-hydroxy-5α-19-norpregnan-20-one 3α-glucuronide
21-acetoxy-11α-fluoro-3β-hydroxy-5α-19-norpregnan-20-one 3β-glucuronide
21-acetoxy-11 α-fluoro-3β-hydroxy-5β-19-norpregnan-20-one 3β-glucuronide
21-acetoxy-12α-fluoro-3α-hydroxy-5β-19-norpregnan-20-one 3α-glucuronide
6α,21-diacetoxy-3α-hydroxy-5β-19-norpregnan-20-one 3α-glucuronide 21-acetoxy-3α-hydroxy-19-norpregn-5(6)-en-20-one 3α-glucuronide21-acetoxy-3β-hydroxy-19-norpregn-5(6)-en-20-one 3β-glucuronide 11α,21-diacetoxy-3α-hydroxy-5β-19-norpregnan-20-one 3α-glucuronide11α,21-diacetoxy-3β-hydroxy-5β-19-norpregnan-20-one 3β-glucuronide11α,21-diacetoxy-3α-hydroxy-5α-19-norpregnan-20-one 3α-glucuronide 11 α, 21 -diaceloxy-3β-hydroxy-5α - 19-norpregnan-20-one 3α-gl ucuronide 11 α, 21-diacetoxy-6α-f luoro-3α-hydroxy-5β-19-norpregnan-20-one 3α-glucu ronide
11α,21-diacetoxy-9α-fluoro-3α-hydroxy-5β-19-norpregnan-20-one 3α-glucu ronide
11α,21-diacetoxy-9α-fluoro-3α-hydroxy-5α-19-norpregnan-20-one 3α-glucu ronide
11α,21-diacetoxy-9α-fluoro-3β-hydroxy-5α-19-norpregnan-20-one 3β-glucuronide
11 α.21-diacetoxy-9α-fluoro-3β-hydroxy-5β-19-norpregnan-20-one 3β-glucuronide
21-acetoxy-3α-hydroxy-5β-19-norpregnane-11,20-dione 3α-glucuronide 21-acetoxy-6α-fluoro-3α-hydroxy-5β-19-norpregnane-11,20-dione 3α-glucuronide
21-acetoxy-9α-fluoro-3α-hydroxy-5β-19-norpregnane-11,20-dione 3α-glucuronide
21-acetoxy-9α-fluoro-3α-hydroxy-5α-19-norpregnane-11, 20-dione 3α-glucuronide
21-acetoxy-9α-fluoro-3β-hydroxy-5α-19-norpregnane-11,20-dione 3β-glucuronide
21-acetoxy-9α-fluoro-3β-hydroxy-5β-19-norpregnane-11,20-dione 3β-glucuronide
21-acetoxy-3α-hydroxy-6α-methyl-5β-19-norpregnan-11,20-dione 3α-glucuronide
21-acetoxy-3α-hydroxy19-norpregn-5(6)-ene-11,20-dione 3α-glucuronide 21-acetoxy-3β-hydroxy19-norpregn-5(6)-ene-11.20-dione 3β-glucuronide

Claims

Claims 1. A therapeutic composition comprising an antithrombotic amount of a steroid having anti-thrombotic activity in combination with an anti-thrombotic
potentiator or a thrombolytic substance.
2. A composition according to claim 1, wherein said steroid is a steroid having a C20-21 steroid
skeleton.
3. A composition according to claim 1, wherein said steroid is a steroid having a pregnane skeleton, in which the angular methyl group at the position 10 may be a hydrogen atom.
4. A composition according to claim 1, wherein said steroid is a steroid having a pregnane skeleton.
5. A composition according to claim 1, wherein said steroid is a steroid having a 17α-H-pregnane
skeleton.
6. A composition according to claim 1, wherein said steroid is a steroid having a 17α-H-pregnane
skeleton which is oxygenated at the positions 3, 20 and 21,
7. A composition according to claim 1, wherein said steroid is a steroid having a 21-hydroxy-17α-H- pregnane-20-one structure which is oxygenated at the position 3, said hydroxyl group being unsubstituted or substituted.
8. A composition according to claim 1, wherein said steroid is a steroid having a 3,21-dihydroxy-17α- H- pregnan-20-one or 21-hydroxy-17α-H-pregn-4-ene- 3,20- dione structure, each of said hydroxyl groups being unsubstituted or substituted.
9. A composition according to claim 1, wherein said steroid is a steroid having a 3,21-dihydroxy-17α- H- pregnan-20-one structure, each of said hydroxyl groups being unsubstituted or substituted.
10. A composition according to claim 1, wherein said steroid is a steroid having a 21-hydroxy- 17α-H- pregn-4-ene-3,20-dione structure, said hydroxyl group being unsubstituted or substituted.
11. A composition according to claim 1, wherein said steroid is a steroid having an 11-nonoxygenated 3,21-dihydroxy-17α-H-pregnan-20-one or 11-nonoxygenated 21-hydroxy-17α-H-pregn-4-ene- 3,20-dione structure, each of said hydroxyl groups being unsubstituted or
substituted.
12. A composition according to claim 1, wherein said steroid is a steroid having an ll-nonoxygenated 3,21-dihydroxy-17α-H-pregnan-20-one structure, each of said hydroxyl groups being unsubstituted or substituted.
13. A composition according to claim 1, wherein said steroid is a steroid having an ll-nonoxygenated 21- hydroxy-17α-H-pregn-4-ene-3, 20-dione structure, said hydroxyl group being unsubstituted or substituted.
14. A composition according to claim 1, wherein said steroid is desoxycorticosterone, 3,21- dihydroxypregnan-20-one or a glucuronide thereof.
15. A composition according to claim 1, wherein said steroid is desoxycorticosterone.
16. A composition according to claim 1, wherein said steroid is 3-glucurono-21-hydroxypregnan- 20-one.
17. The composition of claim 1 comprising heparin or cyclodextrin.
18. A composition according to claim 1, wherein said steroid is a steroid having a C18-21, steroid
skeleton.
19. A composition according to claim 1, wherein said steroid is a steroid having a pregnane skeleton, an estrane skeleton or an androstane skeleton.
20. A composition according to claim 1, wherein said steroid is a steroid having an estrane skeleton.
21. A composition according to claim 1, wherein said steroid is a steroid having an andostane skeleton.
22. A composition according to claim 1, wherein said steroid is a steroid having a 16-alkyl-estrane skeleton.
23. A composition according to claim 1, wherein said steroid is a steroid having a 17-deoxy-estrane skeleton.
24. A composition according to claim 1, wherein said steroid is a steroid having a 16-alkyl-androstane skeleton.
25. A composition according to claim 1, wherein said steroid is a steroid having a 17-deoxy-androstane skeleton.
26. A method for prevention or treatment of thrombosis in a mammal, which comprises administering to said mammal an effective amount of a steroid having antithrombotic acitivty or a pharmaceutically acceptable salt thereof.
27. A method according to claim 26, wherein said steroid is a steroid having a C20-21 steroid skeleton.
28. A method according to claim 26, wherein said steroid is a steroid having a pregnane skeleton, in which the angular methyl group at the position 10 may be a hydrogen atom.
29. A method according to claim 26, wherein said steroid is a steroid having a pregnane skeleton.
30. A method according to claim 26, wherein said steroid is a steroid having a 17α-H-pregnane skeleton.
31. A method according to claim 26, wherein said steroid is a steroid having a 17α-H-pregnane skeleton which is oxygenated at the positions 3, 20 and 21.
32. A method according to claim 26, wherein said steroid is a steroid having a 21-hydroxy-17α-H- pregnane- 20-one structure which is oxygenated at the position 3, said hydroxyl group being unsubstituted or substituted.
33. A method according to claim 26, wherein said steroid is a steroid having a 3,21-dihydroxy-17o- H- pregnan-20-one or 21-hydroxy-17α-H-pregn-4-ene- 3,20- dione structure, each of said hydroxyl groups being unsubstituted or substituted.
34. A method according to claim 26, wherein said steroid is a steroid having a 3,21-dihydroxy-17α-H- pregnan-20-one structure, each of said hydroxyl groups being unsubstituted or substituted.
35. A method according to claim 26, wherein said steroid is a steroid having a 21-hydroxy- 17α-H-pregn-4- ene-3,20-dione structure, said hydroxyl group being unsubstituted or substituted.
36. A method according to claim 26, wherein said steroid is a steroid having an 11-nonoxygenated 3,21- dihydroxy-17α-H-pregnan-20-one or 11-nonoxygenated 21- hydroxy-17α-H-pregn-4-ene- 3 , 20-dione structure, each of said hydroxyl groups being unsubstituted or substituted.
37. A method according to claim 26, wherein said steroid is a steroid having an 11-nonoxygenated 3,21- dihydroxy-17α-H-pregnan-20-one structure, each of said hydroxyl groups being unsubstituted or substituted.
38. A method according to claim 26, wherein said steroid is a steroid having an 11-nonoxygenated 21- hydroxy-17α-H-pregn-4-ene-3, 20-dione structure, said hydroxyl group being unsubstituted or substituted.
39. A method according to claim 26, wherein said steroid is desoxycorticosterone, 3,21-dihydroxypregnan- 20-one or a glucuronide thereof.
40. A method according to claim 26, wherein said steroid is desoxycorticosterone.
41. A method according to claim 26, wherein said steroid is 3-glucurono-21-hydroxypregnan- 20-one.
42. A method according to claim 26 wherein, said steroid is a steroid having a C18-21, steroid skeleeton.
43. A method according to claim 26, wherein said steroid is a steroid having a pregnane skeleton, an estrance skeleton or an androstane skeleton.
44. A method according to claim 26, wherein said steroid is a steroid having an estrane skeleton.
45. A method according to claim 26, wherein said steroid is a steroid having an andostane skeleton.
46. A method according to claim 26, wherein said steroid is a steroid having a 16-alkyl-estrane skeleton.
47. A method according to claim 26, wherein said steroid is a steroid having a 17-deoxy-estrane skeleton.
48. A method according to claim 26, wherein said steroid is a steroid having a 16-alkyl-androstane
skeleton.
49. A method according to claim 26, wherein said steroid is a steroid having a 17-deoxy-androstane
skeleton.
50. A pharmaceutical composition for prevention or treatment of thrombosis comprising an effective amount of a steroid possessing anti-thrombotic activity or a pharmaceutically acceptable salt thereof. This application is a continuation-in-part of my earlier co-pending commonly owned U.S. patent application S.N. 265,590 filed November 1, 1988, which is hereby incorporated by reference. This invention was made, at least in part, using funds from the United States
Government, and the Government has certain rights in the invention.
PCT/US1989/004875 1988-11-01 1989-11-01 Anti-thrombotic steroids WO1990005528A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26559088A 1988-11-01 1988-11-01
US265,590 1988-11-01

Publications (2)

Publication Number Publication Date
WO1990005528A2 true WO1990005528A2 (en) 1990-05-31
WO1990005528A3 WO1990005528A3 (en) 1990-07-12

Family

ID=23011078

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/004875 WO1990005528A2 (en) 1988-11-01 1989-11-01 Anti-thrombotic steroids

Country Status (2)

Country Link
JP (1) JPH03502105A (en)
WO (1) WO1990005528A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114589A1 (en) * 1982-12-20 1984-08-01 The President And Fellows Of Harvard College Inhibition of angiogenesis
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114589A1 (en) * 1982-12-20 1984-08-01 The President And Fellows Of Harvard College Inhibition of angiogenesis
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments

Also Published As

Publication number Publication date
WO1990005528A3 (en) 1990-07-12
JPH03502105A (en) 1991-05-16

Similar Documents

Publication Publication Date Title
JP2620333B2 (en) Drugs for labor induction and abortion and for the treatment of endometriosis and dysmenorrhea, which contain compounds with antigestagen and antiestrogenic activity
US4383992A (en) Water-soluble steroid compounds
Lathe et al. Inhibition of bilirubin conjugation in rat liver slices by human pregnancy and neonatal serum and steroids
CA1330943C (en) Growth inhibiting agent and the use thereof
Naito et al. Steroid hormones inhibit binding of Vinca alkaloid to multidrug resistance related P-glycoprotein
JPH01311030A (en) Angiogenesis inhibiting collagen metabolism control drug
Pincus et al. Biological Activities of Steroids in Relation to Cancer: Proceedings of a Conference Sponsored by the Cancer Chemotherapy National Service Center, National Cancer Institute, National Institutes of Health, US Department of Health, Education and Welfare
Bigsby Progesterone and dexamethasone inhibition of estrogen-induced synthesis of DNA and complement in rat uterine epithelium: effects of antiprogesterone compounds
Basdevant et al. Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel
Rifka et al. Mechanism of interaction of digitalis with estradiol binding sites in rat uteri
Hild et al. CDB-2914: anti-progestational/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits
Helmer et al. Biological activity of steroids as determined by assay of renin-substrate (hypertensinogen)
US4900815A (en) Sulfated polysaccharide DS4152
Nugent et al. A comparative study of the metabolism of hydrocortisone and prednisolone
JP2544136B2 (en) Angiogenesis inhibitor and antitumor agent containing sulfated polysaccharide DS4152
Ely et al. Δ1-Hydrocortisone: Plasma 17-Hydroxycorticosteroid Concentrations Following Oral and IV Administration.
Lerner et al. Biological activities of 16α, 17α dihydroxyprogesterone derivatives
Laurent et al. Catabolism of hyaluronan
Lockwood et al. Biological mechanisms underlying RU 486 clinical effects: inhibition of endometrial stromal cell tissue factor content
Lowy et al. 3H-Corticosterone metabolism in the rat
WO1990005528A2 (en) Anti-thrombotic steroids
Shewell The activity of different steroids in producing thymic involution
Mulrow et al. Conversion of 17-hydroxy-pregnenolone to cortisol by normal and hyperplastic human adrenal slices
Louchart et al. Inactivation of ll-Dehydro-17-Hydroxycorticosterone by Tissue Slices.
US4081538A (en) Aldosterone antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE